Outpatient-based acute HF care calls for development of clinical psychology service for whole-person care provision

Br J Cardiol 2022;29:141–4doi:10.5837/bjc.2022.037 Leave a comment
Click any image to enlarge
Authors:

Acute heart failure (AHF) is associated with 9.3% mortality. Depression and hopelessness are prevalent. We conducted an online survey using Survey Monkey, via the UK Heart Failure (HF) Investigators Research Network of 309 cardiologists, in 2021, to determine: what proportion of UK centres offer outpatient-based management (OPM) for AHF including the use of parenteral diuretics; and what proportion of HF services have clinical psychology support.

There were 51 services that responded, and an estimated 25,135 patients with AHF receive inpatient care per year (median 600 per site). There are 2,631 patients (median 50 per site) treated per year with OPM (9.7% of the population of AHF patients). While 65% of centres provided access to OPM, only 20% have a clinical psychology service.

In conclusion, nearly 10% of patients with AHF receive outpatient-based intravenous diuretic therapy. Only 20% of hospitals have a clinical psychology service for patients who suffer from HF.

Introduction

It is estimated that about 920,000 people are living with heart failure (HF) in the UK.1 According to a National Heart Failure Audit (NHFA) summary report, 74,696 patients were admitted to hospitals in England and Wales due to heart failure between April 2018 and March 2019, representing a 21% rise from a year ago.2 Acute heart failure (AHF) has high mortality of 9.3%,2 and the morbidity is also substantial, including depression and hopelessness.3 Psychological intervention in the form of cognitive behavioural therapy improved quality of life in patients with HF and also led to a reduction in the exploratory outcome of rehospitalisation,3 therefore, excellent whole patient care is essential for the management of AHF, in addition to pharmacotherapy and device treatment.

Acute decompensated heart failure (ADHF), which refers to rapid worsening of HF signs and symptoms, is usually managed in hospital with intravenous (IV) diuretics. HF admissions lead to a significant cost burden to the National Health Service (NHS).4-6 The main focus of ADHF treatment is to control symptoms and improve chances of survival, as well as reduce readmissions. In the era of patient-focused care and economic incentives to reduce hospital admission for HF, there is increasing interest in managing patients with ADHF in outpatient (OP) settings. There is evidence from observational studies that IV diuretics for ADHF in the OP setting is safe and cost-effective,7-12 and a recent systematic review highlights the need for a randomised-controlled trial (RCT) to establish effectiveness of an outpatient management (OPM) strategy for AHF.13 A small pilot RCT in Lancashire, England, in 24 patients randomised to OPM versus standard inpatient care, found that OPM was safe, effective and cost-effective, and improved patient well-being, but this needs confirmation in a large multi-centre RCT, prior to more widespread adoption of this novel treatment strategy.14-16

According to an online survey conducted in the UK in 2016, 24% of the HF centres that participated in the survey provided ambulatory IV/subcutaneous (SC) diuretics for ADHF.17

We conducted an online survey with the objective of capturing data and understanding the current trend of UK HF centres offering IV diuretics for ADHF in different OP settings, and to evaluate the proportion of services that offer a clinical psychology service to HF patients.

Method

A cross-sectional survey titled “Acute Heart Failure IN vs OUT Survey” was conducted online using a Survey Monkey software web link. The link was sent via the UK HF Research Investigators Network to the email addresses of 309 cardiologists in the UK in 2021. In order to maximise the response rate, the survey was sent to 15 Clinical Research Networks (CRN) in England (North East and North Cumbria, North West Coast Yorkshire and Humber, Greater Manchester, East Midlands, West Midlands, West of England, Thames Valley and South Midlands, Eastern, Kent, Surrey and Sussex, Wessex, South West Peninsula, North Thames, South London, North West London). Two authors (AA, KYKW) checked survey data to exclude duplications.

The survey was open for completion from 27 January 2021 to 16 February 2021. The survey had a total of 12 questions and one section at the end to write comments. For five questions, a three-point scale of ‘yes, no and don’t know’ was used. These included whether HF services provide patients access to OP parenteral treatment for ADHF, and availability of a clinical psychology service. Also, respondents were asked whether they were willing to collaborate in a multi-centre observational study to compare inpatient (IP) versus OP treatment for ADHF, and whether they would be willing to be in the steering group of the Safety and effectiveness of Acute heart Failure carE as outpatient (SAFE) RCT – a randomised trial comparing IP versus OPM, and, finally, whether the participants of the survey would like to be sent the report of the survey results. For four questions, participants were asked to write a numeric number as an answer. These included how many ADHF patients receive OP IV diuretics per year, how many patients receive IV diuretics as IP per year, how many patients with ADHF would be eligible to participate in SAFE RCT over two years and, lastly, how many patients the HF services can randomise into SAFE RCT over two years. Three questions were in multiple-choice formats, where responders were given the option to select more than one answer. These included type of OP settings where parenteral diuretics are administered, mode of parenteral diuretics delivery and what healthcare professional is responsible to administer diuretics?

The full survey questionnaire is available in supplementary table 1 (online).

Supplementary table 1. Survey questionnaire

Question number
1 Do your patients have access to outpatient based acute/decompensated heart failure (AHF) service that can deliver parenteral (IV / Subcutaneous)
diuretic treatment?
2 If so, is it based in the hospital (e.g., “frusemide lounge”/ambulatory care centre) or in the community (in a treatment facility) or at home? Check all that apply.
2A Hospital outpatient based (“frusemide lounge”/ambulatory care centre)
2B Community based
2C Home based
2D We do not have such service but hope to develop this service.
2E We do not have such service and don’t know if we should develop this service.
2F Not applicable- we have no intention to develop this service.
3 How many patients with acute heart failure are treated per year by IV diuretics as Outpatients (at home or community centre or ambulatory care/”frusemide lounge” in the hospital)? [Leave blank if not applicable]
4 How many patients with acute heart failure are treated per year by inpatient care?
5 Does your outpatient based AHF service administer IV or subcutaneous diuretic or allow both options?
6 Is IV diuretic treatment administered by HF nurse or “community IV team” or district nurse or other? (Please specify)
7 Do you have a clinical psychology service for patients who suffer from heart failure?
8 Would you like to collaborate in a Multi-centre Observation Study comparing outpatient-based treatment vs. inpatient care for patients with acute/decompensated heart failure?
9 How many patients will be eligible based on the following criteria for recruitment into the “SAFE RCT” over 2 years?

Inclusion criteria:
Patients should have a definite diagnosis of Heart Failure, according to established guideline, requiring at least two more days of IV diuretic treatment.

Exclusion criteria:
1. Unable to travel to and from the treating centre each day (if home-based care is not feasible).
2. Lacks capacity to consent.
3. End stage renal failure requiring renal replacement therapy.
4. Co-morbidities that warrant hospitalisation such as, severe aortic stenosis with planned urgent inpatient surgery.
5. Known COVID-19.

10 How many patients will you be able to RANDOMISE into the “SAFE RCT” over 2 years?
11 Would you like to be in the Open Steering Group for this RCT?
12 Would you like to see a report of this survey?
13 Comments

Statistical analysis

Abdullah - Figure 1. Where is outpatient parenteral diuretic service based?
Figure 1. Where is outpatient parenteral diuretic service based?

Categorical data were expressed as frequency and percentages, and continuous data were shown as median and interquartile range (IQR). The SPSS software (version 27) was used for statistical analysis.

Results

A total of 51 HF services completed the survey. An estimated 25,135 patients per year (median 600 per site, IQR 300–800) receive inpatient care for ADHF; 2,631 patients per year (median 50 per site, IQR 7–100) received OPM for AHF, representing 9.5% of total ADHF population in this survey.

There were 65% (33 of 51) of centres providing access to OPM. Of the 17 which do not (33%), 11 hope to develop this service while four do not know if they should develop this service. Two sites had no intention to develop this service. One centre was not sure whether they have this service.

Table 1. Who delivers the parenteral diuretics?

Number %
Community intravenous team 7 21
Ambulatory team 3 9
Cardiac outpatient nurse 1 3
District nurse 1 3
Heart failure specialist nurse 16 48
Other (not specified) 5 15

The most common site for OP treatment was in hospital settings (furosemide lounge/ambulatory care unit). A number of centres are able to provide parenteral diuretics at home or in the community as shown in figure 1.

The most common route for parental diuretics administration for OPM of ADHF was IV based, although some centres can deliver diuretics SC (20 IV only, seven IV and SC, four SC only, and two ‘don’t know’). Table 1 details which healthcare workers (HCW) are responsible for parenteral OP diuretics.

Ten (20%) of HF centres in the survey offered a clinical psychology service to HF patients, while 6% of centres were not sure whether they have this service.

Twenty-five sites expressed an interest to be in the steering group of the SAFE RCT, and 43 (86%) of the respondents would like to see the report of the survey.

The geographical location of the hospitals offering parenteral diuretics is available in supplementary table 2 (online).

Supplementary table 2. Hospital location by country within the UK.

Country Hospital *
England Barnet Hospital, London
Blackpool Victoria Hospital
Bradford NHS foundation Trust
Broomfield Hospital, Chelmsford
Chelsea and Westminster Hospital, London
Croydon Health Service NHS Trust
Diana, Princess of Wales Hospital, Lincolnshire
Doncaster Bassetlaw Teaching Hospitals NHS Foundation Trust
Glenfield Hospital, Leicester
Hillingdon Hospital, London
Imperial College Healthcare NHS Trust, London
James Cook University Hospital, Middlesbrough
John Radcliffe Hospital, Oxford
King’s College Hospital, London
Lister Hospital, Hertfordshire
London Northwest University Healthcare NHS Trust (Ealing, Northwick Mary’s)
Medway Maritime Hospital, Kent
Northwick Park Hospital, London Northwest University Healthcare NHS Trust
Northern General Hospital, Sheffield Teaching Hospitals NHS Foundation Trust
Northumbria Specialist Emergency Care Hospital
Oxford University Hospitals NHS Foundation Trust
Princess Royal Hospital, Telford
Queen Alexandra Hospital, Portsmouth
Royal Berkshire Hospital, Berkshire
Royal Devon and Exeter NHS foundation Trust
Royal Free Hospital, London
Royal London, Whipps Cross, Newham General, Barts Hospital, London
Royal University Hospitals, Bath
Sandwell and City Hospital Birmingham
Somerset NHS Foundation Trust
Southmead Hospital, Bristol
Southend Hospital/Basildon ECTC
St George’s Hospital, London
The Great Western Hospital, Swindon
Torbay Hospital, Devon
University Hospital of North Tees
University Hospital Southampton
West Middle University Hospital
West Hertfordshire Hospitals NHS Trust
Worcestershire Acute Hospitals NHS Trust
Wycombe Hospital, Buckinghamshire
Wythenshawe Hospital, Manchester
Northern Ireland Ulster Hospital, Dundonald
Scotland Ninewells Hospital, Dundee
Raigmore Hospital NHS Highland
University Hospital Monkland
University Hospital Wishaw NHS Lanarkshire
University Hospital Hairmyres
Wales Princess of Wales Hospital, Bridgend
University Hospital of Wales, Cardiff
* Two respondents did not disclose hospital name

Discussion

According to our 2021 survey, 9.5% of patients with ADHF were treated per year by IV diuretics as outpatients. There are 33 (65%) HF services that provide OPM for ADHF. Of the 17 services that do not currently offer OPM, 11 hope to develop this service. Only 10 (20%) HF services provide clinical psychology support to HF patients. Our survey shows that OPM for ADHF is becoming popular in the UK (65% of respondents indicated this strategy is available for their patients). This contrasted with 25% of HF services (only 14) providing OPM for ADHF in 2016.17

The response rate for our online survey across the UK (<60 responses) is comparable with a similar survey in 2016. In 2016, Mohee and Wong also used SurveyMonkey® (Palo Alto, Calif) for their online survey in 2016. The link was sent to 237 consultant cardiologists with an interest in HF in the UK identified from the Directory of Cardiology 2014. Again, fewer than 60 responded. Nevertheless, it is concerning that despite lack of RCT evidence demonstrating safety and effectiveness, there appears to be a rise in the proportion of centres offering OP-based AHF services. The observational studies suggest that this service may be safe for selected patients.13 However, section bias in observational studies makes it imperative that a multi-centre RCT is performed before results can be generalised. This may be the reason why there are no guidelines supporting the practice.

In the present survey, respondents estimated 25,135 patients per year (median 600 per site) are treated by inpatient care for ADHF; 2,631 patients per year (median 50 per site) receive OPM for ADHF. According to a NHFA summary report, about 74,696 patients were admitted to hospitals in England and Wales due to HF between April 2018 and March 2019. Thus, our sample included a substantial proportion of the total number of patients with AHF in the UK.

A recent systematic review,13 rightly calls for a RCT to establish effectiveness of an OPM strategy for management of AHF. In Mohee and Wong’s 2016 survey, 37.5% expressed interest to participate in a RCT to compare OP versus IP for the management of ADHF. There appears to be rising interest to address this important gap in our knowledge of the best way to deliver treatment for this very common medical problem, as 37 centres (73%) indicated interest to collaborate in a multi-centre RCT comparing the two treatment strategies in our 2021 survey. This may reflect the recognition among a large proportion of HF specialists that there is uncertainty over whether OPM is indeed safe and effective.

Our survey confirms there is uncertainty among the HF community about whether to develop this service. Of the 33% of centres that do not have this service, 11 hope to develop this service, while four do not know if they should develop this service. Two sites had no intention of developing this service. One might expect the true proportion of sites without this service, or which are uncertain about development of OPM, is substantially higher. Those sites may not be interested in completing such a survey. The planned large multi-centre trial will help to resolve the uncertainties HF services have regarding whether to develop OP-based IV diuretic treatment for AHF.

The rising interest of respondents in taking part in an RCT to compare OPM and standard IP care is encouraging. However, it should be noted that this may be because the 2021 survey was sent via the UK HF Research Investigator Network and UK CRNs.

The small pilot trial in Blackpool suggested that OPM is effective, safe and cost-effective, and is a strategy favoured both by patients and carers. Importantly, patients randomised to OPM appeared to enjoy an improvement of their mental well-being. OPM saves the NHS >£2,600 per patient.15 Nevertheless, a word of caution was expressed by the principal author of the pilot trial at the British Cardiovascular Society 2021.16 While patients randomised to OPM appeared to have increased levels of hope initially, by 60 days’ follow-up, their levels of hope dropped, possibly because there was a numerically (albeit not statistically significantly) higher number of readmissions by 60 days. Hopelessness was found to predict death in 2,428 men aged 42–60 years old.18 However, hope, defined as a positive psychology construct, comprises of state hope (which is one’s goal-directed thinking in any given moment and situation), and trait hope (that is a person’s disposition or general way of goal-directed thinking and, hence, more stable).19 Hope is associated with good clinical outcomes in patients with chronic health conditions.20,21 It is, therefore, important to address whole-patient care needs in patients with AHF.

Future directions

Thirty-five centres are interested to collaborate in a multi-centre observational study comparing OPM versus standard IP care for patients with acute/decompensated HF. Furthermore, 37 centres would like to collaborate in a multi-centre RCT comparing the two treatment strategies. An estimated 3,223 patients are eligible to take part in the RCT over two years (median 57 per site, IQR 34–100). The survey respondents estimated they could randomise 1,401 patients into a multi-centre RCT to compare IPM versus OPM for AHF within two years (median 30 per site, IQR 20–50).

In conclusion, OPM for HF with IV diuretics is becoming popular in the UK. Clinical psychology needs expansion to achieve our mission of providing excellent whole-person care for all patients with HF. A multi-centre RCT is needed to compare the safety and cost-effectiveness of OPM versus IP care for ADHF. Our survey suggests such a trial is feasible. It is clear there is a lot of interest among UK HF services to consider establishing OP services for the management of ADHF, and they recognise the need to resolve uncertainties about safety and effectiveness.

Key messages

  • Of the sites that responded, it was estimated that nearly 10% of patients with acute decompensated heart failure (ADHF) are managed with ambulatory parenteral diuretics
  • Before further rapid expansion of outpatient-based intravenous diuretic services in the UK, a multi-centre randomised-controlled trial is urgently needed to test the safety and cost-effectiveness of this innovative service. Our survey suggests such a trial is feasible
  • It is clear there is a lot of interest among UK heart failure services to consider establishing outpatient services for the management of ADHF, and they recognise the need to resolve uncertainties about safety and effectiveness

Conflicts of interest

None declared.

Funding

None.

Acknowledgement

Mr Ben Hardwick, Liverpool Clinical Trials Centre, for helping us send the survey to Clinical Research Networks in England.

Study approval

According to guidance from the Health Research Authority, our study type will not be considered as research and as such would not require any approval.22

References

1. British Heart Foundation. Heart failure hospital admissions rise by a third in five years. 4 November 2019. Available at: https://www.bhf.org.uk/what-we-do/news-from-the-bhf/news-archive/2019/november/heart-failure-hospital-admissions-rise-by-a-third-in-five-years

2. National Institute For Cardiovascular Outcomes Research (NICOR). National Heart Failure Audit (NHFA): 2020 summary report (2018/19 data). London: Healthcare Quality Improvement Partnership (HQIP), 2020. Available from: https://www.nicor.org.uk/wp-content/uploads/2020/12/National-Heart-Failure-Audit-2020-FINAL.pdf

3. Sbolli M, Fiuzat M, Cani D et al. Depression and heart failure: the lonely comorbidity. Eur Heart J 2020;22:2007–17. https://doi.org/10.1002/ejhf.1865

4. British Heart Foundation. Heart statistics. Available at: https://www.bhf.org.uk/what-we-do/our-research/heart-statistics [accessed 19 June 2021].

5. Desai AS, Stevenson LW. Rehospitalization for heart failure. Circulation 2012;126:501–06. https://doi.org/10.1161/CIRCULATIONAHA.112.125435

6. Afari ME, Aoun J, Khare S, Tsao L. Subcutaneous furosemide for the treatment of heart failure: a state-of-the art review. Heart Fail Rev 2019;24:309–13. https://doi.org/10.1007/s10741-018-9760-6

7. Ioannou A, Browne T, Jordan S et al. Diuretic lounge and the impact on hospital admissions for treatment of decompensated heart failure. QJM 2020;113:651–6. https://doi.org/10.1093/qjmed/hcaa114

8. Buckley LF, Seoane-Vazquez E, Cheng JWM et al. Comparison of ambulatory, high-dose, intravenous diuretic therapy to standard hospitalization and diuretic therapy for treatment of acute decompensated heart failure. Am J Cardiol 2016;118:1350–5. https://doi.org/10.1016/j.amjcard.2016.07.068

9. Ryder M, Murphy NF, McCaffrey D et al. Outpatient intravenous diuretic therapy: potential for marked reduction in hospitalisations for acute decompensated heart failure. Eur Heart J 2008;10:267–72. https://doi.org/10.1016/j.ejheart.2008.01.003

10. British Heart Foundation. Learning points for the successful introduction of Intravenous diuretics in the community. London: BHF, 2015. Available from: https://www.bhf.org.uk/informationsupport/publications/healthcare-and-innovations/learning-points-for-the-successful-introduction-of-intravenous-diuretics-in-the-community

11. British Heart Foundation. Treating heart failure patients in the community with intravenous diuretics. London: BHF, 2015. Available from: https://www.bhf.org.uk/informationsupport/publications/healthcare-and-innovations/intravenous-diuretics-in-the-community_sirivd1

12. Ahmed FZ, Taylor JK, John AV et al. Ambulatory intravenous furosemide for decompensated heart failure: safe, feasible, and effective. ESC Heart Failure 2021;8:3906–16. https://doi.org/10.1002/ehf2.13368

13. Wierda E, Dickhoff C, Handoko ML et al. Outpatient treatment of worsening heart failure with intravenous and subcutaneous diuretics: a systematic review of the literature. ESC Heart Fail 2020;7:892–902. https://doi.org/10.1002/ehf2.12677

14. Wong K, Latt NKZ, Debski M et al. Safety and effectiveness of outpatient based acute heart failure care: a randomised controlled feasibility trial. Heart 2020;106(suppl 2):A74–A75. https://doi.org/10.1136/heartjnl-2020-BCS.96

15. Wong K, Assaf O, Latt NKZ et al. Is outpatient based acute heart failure treatment cost-effective? An analysis based on a pilot prospective trial. Heart 2020;106(suppl 2):A73–A74. https://doi.org/10.1136/heartjnl-2020-BCS.95

16. Wong K, Hughes DA, Debski M et al. Does outpatient based IV diuretic treatment for acute heart failure give patients hope. Heart 2021;107(suppl 1):A116–A117. https://doi.org/10.1136/heartjnl-2021-BCS.149

17. Mohee K, Wong K. Are we ready for outpatient acute heart failure management (frusemide lounges and beyond)? A nationwide survey of UK acute heart failure practice. Heart 2016;102(suppl 6):A6-A7. https://doi.org/10.1136/heartjnl-2016-309890.9

18. Everson S, Goldberg D, Kaplan G et al. Hopelessness and risk of mortality and incidence of myocardial infarction and cancer. Pyschosom Med 1996;58:113–21. https://doi.org/10.1097/00006842-199603000-00003

19. Snyder CR. Handbook of hope: theory, measures, and applications. San Diego, CA: Academic Press, 2000.

20. Billington E, Simpson J, Unwin J, Bray D, Giles D. Does hope predict adjustment to end-stage renal failure and consequent dialysis? Br J Health Psychol 2008;13:683–99. https://doi.org/10.1348/135910707X248959

21. Kortte KB, Stevenson JE, Hosey MM, Castillo R, Wegener ST. Hope predicts positive functional role outcomes in acute rehabilitation populations. Rehabil Psychol 2012;57:248–55. https://doi.org/10.1037/a0029004

22. Health Research Authority. What approvals and decisions do I need? https://www.hra.nhs.uk/approvals-amendments/what-approvals-do-i-need/

Should we be screening people with diabetes for atrial fibrillation? Exploring patients’ views

Br J Cardiol 2022;29:145–9doi:10.5837/bjc.2022.038 Leave a comment
Click any image to enlarge
Authors:

Atrial fibrillation (AF) and diabetes are increasingly prevalent worldwide, both increasing stroke risk. AF can be detected by patient-led electrocardiogram (ECG) screening applications. Understanding patients’ views around AF screening is important when considering recommendations, and this study explores these views where there is an existing diagnosis of diabetes.

Nine semi-structured qualitative interviews were conducted with participants from a previous screening study (using a mobile ECG device), who were identified with AF. Thematic analysis was completed using NVivo 12 Plus software and themes were identified within each research question for clarity.

Themes were identified in four groups:

  1. patients’ understanding of AF – the ‘concept of irregularity’ and ‘consideration of consequence’;
  2. views on screening – ‘screening as a resource-intensive initiative’, ‘fear of outcomes from screening’ and ‘expectations of screening reliability’;
  3. views on incorporating screening into routine care – ‘importance of screening convenience’; and
  4. views on the screening tool – ‘technology as a barrier’ and ‘feasibility of the mobile ECG recording device for screening’.

In conclusion, eliciting patients’ views has demonstrated the need for clear and concise information around the delivery of an AF diagnosis. Screening initiatives should factor in location, convenience, personnel, and cost, all of which were important for promoting screening inclusion.

Introduction

There is an increasing prevalence of atrial fibrillation (AF) worldwide, with a one-in-three lifetime risk of developing AF over the age of 40 years.1 AF is a leading cause of stroke, and stroke risk is increased further in the presence of diabetes.2 Diabetes has been recognised as a risk factor for AF and, therefore, targeted screening for AF in such groups has been explored in combination with comorbid risk factors.2

There are yet to be universally accepted recommendations for AF screening. The European Society of Cardiology (ESC) recommend opportunistic screening in people >65 years and consideration of systematic screening when >75 years, or in those at higher risk of stroke.3 The AF-SCREEN collaboration promotes worldwide implementation of AF screening in people >65 years.4 Furthermore, Public Health England incorporate AF within their ‘ABC’ (Atrial fibrillation, Blood pressure, Cholesterol) campaign for cardiovascular disease prevention, with emphasis on nationwide screening.5

Opportunities for AF screening are enhanced through commercialisation of digital monitoring applications.6 Many of these can be patient-initiated, and it is, therefore, important to understand patients’ views of AF screening. The views of population groups likely to undergo AF screening is needed to inform screening recommendations relating to acceptability and engagement with implementation programmes.

This qualitative study explores patients’ views and experiences of AF screening and understanding of AF (from screened patients in the previous study).7 Patients’ views on how we can incorporate screening into routine care and the screening tool used to detect AF in the aforementioned research are also sought in this study.

Research questions

The research questions for this study are:

  • What do patients understand of AF?
  • What are patients’ views on screening for AF, particularly when diabetes is an existing condition?
  • How do patients view screening tools for AF? Is this seen as a beneficial and tolerable approach?

Method

Study design and study materials

Table 1. Interview schedule

  1. I’d like to ask you about the day you had the AF screening. What happened during the screening episode? What do you remember about the information given beforehand?
  2. What is your understanding of atrial fibrillation?
  3. What are your views about screening for health conditions in general?
  4. What are your views about screening for atrial fibrillation? (Consider benefits and negatives of screening as prompts.)
  5. Before you took part in the first part of this study, had you considered the relationship between diabetes and AF? Can you tell me why you think this?
  6. How do you think we could include screening into routine care?
  7. What are your thoughts on the screening device used to record your heart rhythm (ECG) in the screening study? If this device was available to screen again, how would you feel about using this for further screening?
  8. Did you have any reservations about taking part and if so, can you tell me a bit about them?
  9. Do you have any regrets about taking part and if so, can you tell me a bit about them?
  10. Is there anything else you would like to share about your participation in the atrial fibrillation screening study or your thoughts about atrial fibrillation?

This study adopted a qualitative design, with one-to-one in-depth semi-structured interviews with patients who had diabetes, and then a diagnosis of AF from the screening study. The interview schedule is set out in table 1.

Recruitment and sample

Patients were recruited from a previous screening study, all of whom were eligible for inclusion in this current study and who had been identified as having AF.

Eligible participants were invited by telephone then sent an information letter and consent form. After a two-week reflection period, invitees were telephoned again to confirm consent. Consenting participants returned a signed consent form in a stamped-addressed envelope and a time convenient to the participant scheduled for interview. Of the 16 eligible participants, nine were interviewed (two had died, four were uncontactable and one declined).

Procedure

Interviews were conducted over the telephone and audio recorded. Recordings were transcribed verbatim and anonymised (by assigning identification numbers). Interview duration ranged from 30 to 60 minutes. Interviews were conducted by the first author (AH), using the semi-structured interview guide (table 1). Open-ended questions allowed for new areas of conversation to emerge and then explore.

Data analysis

NVivo 12 Plus qualitative data analysis software (QSR International) was used to support inductive and deductive thematic analysis of the transcripts. Thematic analysis involved reading each transcript carefully and repeatedly, identifying patterns and assigning codes.8 Initially, this was through reading line-by-line, using descriptive labels and coding schema, then iteratively refined. Themes and sub-themes were then developed inductively from the data, focusing on factors participants’ spoke about in greater depth, rather than their prevalence (although there was some correlation). When no new data, themes or relationships could be identified, no further data analysis was undertaken. As a specialist in the management of AF, the lead researcher (AH) had an in-depth understanding of AF and tried to impose no influence during interviews, but there may have been inference through phrasing, due to predetermined expectations.

Results

Of the nine participants, eight were male and the mean age was 69 years (range 53–86). Developed themes were assigned within each of the research questions with sub-themes where appropriate. (Numbers in brackets identify the participant.)

Patients’ views on AF

Theme: the concept of irregularity

Patients were asked about their understanding of AF. All participants knew this related to their heart and some mentioned an irregularity.

  • “Well it’s an electrical irregularity and I’m taking blood thinners for it.” (2)
  • “It’s something to do with an irregular movement [of the heart valve].” (7)

Varying descriptions demonstrated different levels of understanding including mention of double heartbeats, too much blood flowing through the heart, one side of the heart not running properly or at the right beat, and the heart pumping too fast.

Theme: consideration of consequence

Infrequently, blood-thinning medications were identified as relatable to AF, with one participant mentioning this among their treatments and another naming their anticoagulant, but nobody directly referred to stroke. AF was considered a consequence of stress or high blood pressure by two participants. A ‘leakage of water’ in the legs was also considered to relate to AF by either the arrhythmia causing the water leakage or vice versa.

  • “…I mean apparently I’ve had this problem for quite a long time and it was caused through stress and anxiety.” (4)
  • “…I’m taking blood thinners for it which makes it easier to be pumped round…” (2)

This varying recall of information was apparent, despite all participants being informed by the lead researcher (AH) at the time of screening and diagnosis, having an AF information sheet and visiting their GP for follow-up consultation. Some also had subsequent visits to the hospital for cardiac investigations.

Patients’ views on health screening and screening for AF

When asked about health screening in general, patients were able to draw on experiences of screening for their heart and diabetes and their insights may, therefore, represent the demographics of this population. For example, participants talked of their comorbid conditions, making reference to blood glucose monitoring or retinal eye screening.

Theme: screening as a resource-intensive initiative

Factors relating to resource included cost of screening for the test, the appointment, the location and getting to the location. Cost saving was talked of for longer-term benefits.

  • “You gotta think of the cost… the amount of people, the number of appointments mucks the hospital up. I don’t know what it costs for every appointment at the hospital. Must be a hundred quid.” (6)
  • “Doesn’t take any time and you’d err you’d soon see trends building up. It could save a fortune.” (2)

Without prompting, reference was made to the appropriate age of people to undergo screening, in general, and in relation to AF.

  • “Well maybe some of it could be when you get to a certain age maybe the doctors could do a bit of a screening could they? [The interviewer asked what age they thought would be appropriate]. Umm, say 50, 55 I suppose.” (6)
  • “…certainly if you’re over 50 or whatever, you can do a lot of simple screening on your phone.” (2)
Theme: fear of outcomes from screening

Patients reported disparate expectations ranging from fear around screening engagement, to wider benefits in relation to their own health. The ‘necessity’ of knowing about health conditions was reported. None of the participants regretted taking part and all preferred to know about their diagnoses.

  • “It if helps people find out about stuff, if you’re not a guinea pig you might not find about cancer or things… That thing you did with me [referring to the Kardia® heart rhythm recording], I wasn’t worried about it. If you don’t do it, you don’t know.” (6)
  • “…the benefits of that are you know your heart’s not running properly so it could be put back into the right way, so it’s running right again.” (6)

When asked about reservations of taking part, one participant explained they were wary of the screening invite and wondered if it was a ‘scam’.  This was not, however, related to previous screening invites, but was compared to promotional offers of help.

Screening follow-up including appointments, time off work and consequence, was included in responses, although these were from hypothetical scenarios, rather than personal experiences.

  • “…still too many people in the United Kingdom are afraid of discovering something is wrong… they’re worried about taking time off work and the whole thing, they’re worried about taking up the doctor’s time…worried they won’t get an appointment and waiting lists… sort of universe of distracting concerns…” (9)
Theme: expectations of screening reliability

Lack of education around the benefits of health screening was shared by one participant, who felt that their scientific and medical model beliefs, lead to their desire for knowledge [of the presence or absence of disease]. The accuracy of ECG screening and monitoring was considered reliable by the same participant, but less so by another. Another patient recognised that things could change over time, with one screening episode not being sufficient or accurate.

  • “Any form of screening is a good thing and because 99 err 90 per cent of the time umm nothing was detected then all of a sudden there’s a change in the readings…” (2)

Patients’ views on how we can incorporate screening into routine care

Theme: the importance of screening convenience

Views on screening location revealed that visiting the GP for this purpose was more favourable than the hospital, which was seen as a deterrent to screening opportunities due to logistical difficulties, access, transport, and parking. One patient commented that they would not attend if invited to hospital-based screening. GP screening was mentioned most frequently with other clinically relevant departments also suggested, e.g. ophthalmology and the diabetes centre. The viewpoint that healthcare is too centralised to hospitals was voiced, and the need to decentralise by incorporating community GP-based screening was emphasised.

  • “…if I get a letter from the hospital saying we are doing XY and Z screening please make an appointment for screening, I throw it in the bin.” (9)

Convenience seemed to directly relate to patient motivation with attitudes towards health beliefs contributing to involvement. A dedicated screening centre was suggested, as was a mobile screening unit. Incorporating screening into existing appointments was suggested as an effective approach for encouraging participation.

  • “It’s a good thing because as I say, I go for my three-month to see my GP and he checks me out and … they put all the machines on you.” (7)

The patient–professional relationship was felt relevant to the success of screening opportunities, and if offered by a healthcare provider they trust, might entice involvement.

Patients’ views on the screening tool (a single-lead mobile ECG recording device)

Theme: technology as a barrier

Familiarity with screening devices varied, with some participants relaying benefits to health screening and self-monitoring, particularly in the presence of multi-morbidity. One patient explained the presence of diabetes and AF alongside respiratory disease, and that this encouraged their use of home monitoring devices and associated technology.

  • “Well I have a blood pressure monitor and a blood oxygen monitor and I have my blood sugar monitor and I use them.” (9)

Technology know-how was reported as a potential barrier to screening tools, as was older age. Younger people with familiarity around apps and mobile health was emphasised. This was considered important to encourage health monitoring, lifestyle, and behaviour modification, with an overall proactive approach to modern healthcare. The focus on age was not, however, echoed across the group with participants stating their confidence with mobile phones and health-related applications, despite being of older age.

There was existing familiarity with the Kardia® device specifically, with some reporting previous use or, at least, visualisation of the device in the public domain.

Theme: feasibility of the mobile ECG recording device for screening

The ability to use the device at home for repeated recordings was suggested, with recordings then shown to the GP for surveillance along with, for example, blood pressure monitoring. The portability of the device was attractive, along with ease of use, convenience and comfort.

This ease and convenience were encouraging when frequency of screening was contemplated. Using the device once a week was suggested, but nobody commented on using it during symptoms, such as palpitations.

  • “…you can keep it handy, put it in a drawer and do it once a week… Yeah, I suppose about once a week would be about right.” (6)

One participant felt the device was good, if it was accurate. Another felt the accuracy was probably not entirely reliable, but was good enough to detect a problem, which could lead to further investigations.

Discussion

Previous research has shown that patients who have a good understanding of AF, report greater acceptance, fewer symptoms, enhanced coping mechanisms and less negative emotions related to the arrhythmia.9 Patients’ understanding and interpretation of AF in this study, which was limited in content and knowledge, is therefore relevant. All patients were provided with the same information and asked to see their GP. The researcher (AH) explained the diagnosis of AF verbally to support the information provided, which appeared to be understood at the time, but not retained.

Stroke was not mentioned, although two participants mentioned taking blood-thinning medicines. This limited understanding of stroke risk is concerning, and may be a factor in treatment adherence. Previous research regarding patients’ understanding of AF showed that many were unaware of the name of the condition.10 Another study showed that patients had difficulty understanding the need for anticoagulation, particularly when advised as a life-long treatment.11 It may, however, be that this was inadequately explained rather than related to patient comprehension. A study whereby patients were interviewed following a recent diagnosis of AF, described ‘knowledge deficit’ two weeks after the AF diagnosis, relating to AF symptoms, medications and stroke risk.12 Another study considered patients’ understanding at the time of the emergency department visit, then three months later and concluded similar findings.13 This link with health knowledge and health status has been well documented and can result in under-utilisation of preventative resources including screening.14

Further considerations around this lack of perceived awareness of AF and stroke risk, could be, in part, due to the asymptomatic nature of their arrhythmia. None of the interviewed patients commented on problems relatable to AF. None had needed specialist input and, when screened in the original AF study, were haemodynamically stable with normal physiological measurements (besides the AF heart rhythm tracing), exhibiting and reporting no symptoms. It is possible that patients with symptoms of AF, requiring specialist intervention, complex medication management or sequelae of their arrhythmia would be more familiar with the condition and treatments, as opposed to those in this cohort. While there is little evidence to support this in existence, experience of symptoms could improve understanding, and so, health literacy.

Recommendations regarding appropriate patient information for AF have been published elsewhere, and include keeping pathophysiological information basic.15 Learning how much the patient wishes to know is important, along with situating information within the contextual factors (social and psychological) that effect experience and understanding of symptoms, physiological mechanisms, and psychosocial factors. Using a variety of media platforms can be beneficial according to patients’ preferences.

Screening for AF was generally regarded positively in this research, and all participants were pleased to have knowledge of the arrhythmia. There was, however, acknowledgement that not everyone may be open to accepting a new diagnosis or entering screening programmes. Cost featured heavily in terms of resource and screening approach, but cost savings were also noted. Screening location was preferred at a GP practice or similar outpatient-based environment, and hospitals regarded as a deterrent to screening opportunities. As screening approaches evolve, an expanded role within primary care can be anticipated, but this incorporation may place additional strain on already stretched systems.16 Evidence on the effective implementation of screening in primary care is required to ensure efficient use of resources, beyond consideration of the screening tool that has been a focus in heart rhythm screening research.

The ECG recording device was viewed positively by all participants, with comments relating to ease of use, portability, comfort, perceived accuracy, convenience and being patient-led. Technology know-how was considered essential when patient-led, but not a barrier, with many reporting mobile phone and digital technology familiarity. This concurs with acceptance of screening devices by participants in large-scale trials.17,18

Limitations

Further research exploring patient views, particularly in relation to risk-factor modification, would be beneficial. This research did not include questions around causes or symptoms. The sample included people who had agreed to participate in a screening programme who had diabetes and, therefore, may not be transferable to other patient groups. All but one participant was male and, therefore, female views were less represented. Female participants may have had different interpretations of screening due to female-orientated screening programmes. All interviewed participants had AF, but widening this to screened groups who did not have AF, or who had not undergone specific screening, might offer valuable data in terms of AF screening considerations.

Conclusion

This study highlights that patients’ understanding of AF varies, and AF consequences, such as stroke, did not feature when exploring their views. Supporting patients to comprehend possible causes of AF, modifiable risks and treatment options is imperative for adherence and working in partnership, to reduce sequelae and improve quality of life.

Understanding patients’ views of AF screening, including barriers, is important when planning screening programmes. Employing tools that are valid, while easy to use, offers further opportunity for AF screening.

Key messages

  • Atrial fibrillation (AF) and diabetes are increasing in prevalence and are risk factors for stroke. Patients’ understanding of their AF is important for treatment concordance
  • Patients’ views on screening for AF demonstrate this as an accepted and beneficial undertaking, with screening tools and location important for screening attendance
  • Incorporating patients’ views and experiences is essential within patient-orientated practice and research, and outcomes should be applied to the design of screening programmes

Conflicts of interest

None declared.

Funding

None.

Study approval

Ethical approval was granted by the Faculty of Health and Medicine Research Ethics Committee at the University of Lancaster (Ref: FHMREC20156) and the Health and Community Service Research Ethics Committee in Jersey (Ref: 2021/HCSREC/02).

References

1. Mairesse G, Moran P, Van Gelder I et al. Screening for atrial fibrillation: a European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulacion Y Electrofisiologia (SOLAECE). Europace 2017;19:1589–623. https://doi.org/10.1093/europace/eux177

2. Wild S, Roglic G, Green A, Sircee R, King H. Global prevalence of diabetes: estimates for year 2000 and projections for 2030. Diabetes Care 2004;21:1047–53. https://doi.org/10.2337/diacare.27.5.1047

3. Hindricks G, Potpara T, Dagres N et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2020;42:373–498. https://doi.org/10.1093/eurheartj/ehaa612

4. Freedman S, Camm J, Calkins H et al. Screening for atrial fibrillation. A report of the AF-SCREEN International Collaboration. Circulation 2017;19:1851–67. https://doi.org/10.1161/CIRCULATIONAHA.116.026693

5. UK Health Security Agency. The 10-year CVD ambitions for England – one year on. Blog, 6 February 2020. Available at: https://publichealthmatters.blog.gov.uk/2020/02/06/the-10-year-cvd-ambitions-for-england-one-year-on [accessed on 26 April 2021].

6. Richardson E, Hall A, Mitchell A. Screening for atrial fibrillation and the role of digital health technologies. In: Cismaru G, Chan KA, eds. Epidemiology and Treatment of Atrial Fibrillation. London: IntechOpen Limited, 2020. https://doi.org/10.5772/intechopen.88660

7. Hall A, Mitchell A, Ashmore L, Wood C. Atrial fibrillation prevalence and predictors in patients with diabetes: a cross-sectional screening study. Br J Cardiol 2022;29:21–5. https://doi.org/10.5837/bjc.2022.008

8. Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol 2006;3:77–101. https://doi.org/10.1191/1478088706qp063oa

9. McCabe P. Predictors of symptoms and psychological distress in patients with recurrent symptomatic atrial fibrillation [doctoral dissertation]. Omaha, NE: University of Nebraska Medical Centre, 2009.

10. Lip G, Kamath S, Jafri M et al. Ethnic differences in patient perceptions of atrial fibrillation and anticoagulation therapy: the West Birmingham atrial fibrillation project. Stroke 2002;22:238–42. https://doi.org/10.1161/hs0102.101817

11. Thrysoee L, Stromberg A, Brandes A et al. Management of newly diagnosed atrial fibrillation in an outpatient clinic setting – patients’ perspectives and experiences. J Clin Nurse 2018;27:601–11. https://doi.org/10.1111/jocn.13951

12. McCabe P, Schad S, Hampton A, Holland D. Knowledge and self-management behaviours of patients with recently detected atrial fibrillation. Heart Lung 2008;37:79–90. https://doi.org/10.1016/j.hrtlng.2007.02.006

13. Koponen L, Rekola L, Ruotsalainen T et al. Patient knowledge of atrial fibrillation: 3 month follow up after an emergency room visit. J Adv Nurs 2007;61:51–61. https://doi.org/10.1111/j.1365-2648.2007.04465.x

14. Berkman N, Dewalt D, Pignone M et al. Literacy and health outcomes. Evid Rep Technol Assess (Summ) 2004;87:1–8. Available from: https://www.ncbi.nlm.nih.gov/books/NBK37134/

15. McCabe P, Barnason S, Houfek J. Illness beliefs in patients with recurrent symptomatic atrial fibrillation. Pacing Clin Electrophysiol 2011;34:810–20. https://doi.org/10.1111/j.1540-8159.2011.03105.x

16. Rao M, Pilot E. The missing link – the role of primary care in global health. Glob Health Action 2014;7:23693. https://doi.org/10.3402/gha.v7.23693

17. Lowres N, Krass I, Neubeck L et al. Atrial fibrillation screening in pharmacies using an iPhone ECG: a qualitative review of implementation. Int J Clin Pharm 2015;37:1111–20. https://doi.org/10.1007/s11096-015-0169-1

18. Svennberg E, Engdahl J, Al-Khalili F et al. Mass screening for untreated atrial fibrillation: the STROKESTOP study. Circulation 2015;131:2176–84. https://doi.org/10.1161/CIRCULATIONAHA.114.014343

Patient satisfaction with telephone consultations in cardiology outpatients during the COVID-19 pandemic

Br J Cardiol 2022;29:150–3doi:10.5837/bjc.2022.039 Leave a comment
Click any image to enlarge
Authors:

The COVID-19 pandemic required a radical change in healthcare delivery methods, including the remote delivery of many outpatient services. We aimed to understand patient satisfaction with telephone consultations.

Patients who had undergone a cardiology telephone consultation between 24 February and 19 July 2021 were asked to complete a survey. The survey assessed their satisfaction with the consultation and their preference between remote and face-to-face consultation. The 56 responses demonstrated high levels of satisfaction with 56% agreeing they were “completely satisfied” with the consultation compared with 5% who disagreed. However, 63% would have preferred a face-to-face appointment compared with 22% preferring a telephone consultation.

No patterns were observed that might help to guide who should be offered the different modalities of consultation; to maximise patient satisfaction a flexible and individualised approach is likely to be required.

Background

The COVID-19 pandemic dramatically affected many aspects of everyday life and necessitated rapid changes to healthcare delivery. Health systems around the world started to rely more heavily upon remote consultations for safe healthcare delivery.1

Despite the clear advantage of limiting movement, and, hence, reducing the risks of either contracting or spreading COVID-19, a transition to remote consultations must be treated with caution. Research in primary care prior to the pandemic found that doctors were less likely to exclude serious illness when consultations were conducted by telephone rather than face-to-face.2

Alongside the safety of remote consultations, a key consideration must be patient satisfaction. If remote consultations are not acceptable to patients there will be an inevitable erosion of the doctor–patient relationship and a consequent reduction in the quality of care provided. Although high levels of satisfaction have been reported in both medical and surgical specialities across Europe,3-5 a number of studies have found that face-to-face appointments were preferred by patients.6-8

As the restrictions imposed due to the COVID-19 pandemic are eased around the world, a question has arisen as to the degree to which remote consultations should remain a part of outpatient services. Understanding more about the contexts where remote consultation may be appropriate and acceptable to patients is crucial.

At the start of the pandemic, along with almost all National Health Service (NHS) outpatient departments, the cardiology department at Whiston Hospital (a district general hospital in the Northwest of England) arranged for a majority of appointments to be conducted by telephone. We aimed to understand the impact that this would have on patient satisfaction with this service, and whether there were any significant predictors of the levels of satisfaction.

Method

All consultants in the cardiology department of Whiston Hospital were invited to participate in this survey, although none were obliged to do so. At the end of outpatient telephone consultations, verbal consent for participation was obtained from patients. The survey was posted along with an information sheet detailing the purpose of the study and emphasising the voluntary nature of participation. All responses were completed anonymously. Local approval was obtained from the Trust’s Research and Development and Information Governance departments.

The first part of the survey consisted of basic demographic information and ascertained whether this was their first consultation or a follow-up. The second part consisted of sixteen questions, of which thirteen were taken from the Consultation Satisfaction Questionnaire (CSQ).9 The CSQ is a validated tool that is widely used to assess patient satisfaction with a specific clinical encounter, and assesses patient satisfaction in four domains: general satisfaction, professional care, depth of relationship, and perceived time.

The three remaining questions directly asked the patient’s opinion of the telephone consultation: whether they would have preferred a face-to-face consultation; whether they felt safer with a telephone consultation; and whether a telephone consultation was more convenient.

All questions were answered on a five-point Likert scale from 1 (strongly disagree) to 5 (strongly agree). The CSQ was modified to remove questions not relevant to telephone consultations.

Surveys were sent out to consenting patients between 24 February and 19 July 2021 (the end date corresponding to the initial lifting of most legal restrictions in England relating to the COVID-19 pandemic).

A mean response was calculated to questions from each of the four domains of the CSQ, with scores from the negatively phrased questions inverted. Differences in the responses to each of these domains was assessed by the Friedman test. Post-hoc analysis was performed with Nemenyi tests with the Bonferroni correction applied. Data were assumed to be missing at random and were not imputed.

All statistical analyses were performed, and graphics generated using R version 4.0.0 (R Foundation for Statistical Computing; http://www.r-project.org/).

Results

Local context

During the study period in Knowsley (the local authority region which contains the hospital and much of its catchment area), the median number of daily COVID-19 cases was eight (interquartile range [IQR] 3–30.25). The trend of local cases closely matched the national picture, with a rise in cases in both January 2021 (peak 374 per day) and January 2022 (peak 1,009 per day).10

At the start of the survey 46.5% of residents in Knowsley had received at least one dose of COVID-19 vaccination, compared with 32.7% of the whole of England.10

Demographics

During the study period, 157 patients consented to have a survey posted out to them, from which 56 surveys were returned (36% return rate). Of the respondents, 22 (39%) were female. The median age range was 66–75 years (with none younger than 46 or older than 95 years). Seventeen (30%) reported that they had a disability, of which 16 were physical and one was sensory. Of the respondents, 55 (98%) reported their ethnicity as White British and one as Black British.

Consultation satisfaction

Overall satisfaction levels were high with 36 (64%) patients selecting ‘agree’ or ‘strongly agree’ to the question “I am completely satisfied with my consultation with the doctor”, compared with only three (5.4%) selecting ‘disagree’ and none selecting ‘strongly disagree’.

An average response was calculated for each of the four domains in the CSQ and the responses are shown in a ridge plot in figure 1.

Goodall - Figure 1. Ridge plot of the average responses to the four categories of the Consultation Satisfaction Questionnaire (CSQ). A score of 5 would equate to full satisfaction and a score of 1 to full dissatisfaction
Figure 1. Ridge plot of the average responses to the four categories of the Consultation Satisfaction Questionnaire (CSQ). A score of 5 would equate to full satisfaction and a score of 1 to full dissatisfaction

There was a significant difference between the responses to each category by the Friedman rank-sum test (p<0.001). In post-hoc analysis, the only statistically significant differences were that both general satisfaction (median 3.67, p=0.008) and professional care (3.75, p<0.001) were rated more favourably than perceived time (median 3.0).

Telephone consultation

When asked if they would have been more satisfied with a face-to-face appointment, 34 (63%) either agreed or strongly agreed, while only 12 (22%) disagreed or strongly disagreed (figure 2).

Goodall - Figure 2. Responses to survey questions regarding telephone consultations. Numbers on the right-hand side correspond to the number of responses provided for each question
Figure 2. Responses to survey questions regarding telephone consultations. Numbers on the right-hand side correspond to the number of responses provided for each question

When asked if a telephone consultation was more convenient 21 (39%) either agreed or strongly agreed versus 18 (33%) who disagreed or strongly disagreed. When asked if they felt safer with a telephone consultation 20 (36%) agreed or strongly agreed versus 21 (38%) who disagreed or strongly disagreed.

Three of the 34 respondents stated that they would have preferred a face-to-face appointment despite reporting that a telephone appointment was more convenient. Similarly, seven of the 34 who would have preferred a face-to-face consultation thought this despite thinking that a telephone consultation was safer.

An average response to the three questions in figure 2 was calculated. Here, a score of 5 equates to a universal preference for telephone consultations and a score of 1 equates to a universal preference for face-to-face consultations. Comparable preferences between telephone consultations and face-to-face consultations were seen between those younger and older than 65 years; male and female; with and without disability; and between those consulting a cardiologist for the first time and those attending for a follow-up appointment. These responses are shown in swarm plots (online appendix).

Goodall - Appendix. Swarm plots of patients’ consultation preference. 5 equates to a universal preference for telephone consultations, and 1 to a universal preference for face-to-face consultations. Comparisons between A: Age; B: Sex; C: Disability; D: Whether this was the first consultation with a cardiologist or a follow-up appointment
Appendix. Swarm plots of patients’ consultation preference. 5 equates to a universal preference for telephone consultations, and 1 to a universal preference for face-to-face consultations. Comparisons between A: Age; B: Sex; C: Disability; D: Whether this was the first consultation with a cardiologist or a follow-up appointment

Discussion

This survey found overall high levels of consultation satisfaction. However, a majority of patients would have preferred for the consultation to be conducted face-to-face.

With a median age range of 66–75 years, the population studied was older than the current UK median age of 40.0 years,11 although likely broadly representative of those attending adult outpatient clinics. There was also a notable predominance of patients with a white British ethnicity, reflecting the relatively low levels of ethnic diversity in the hospital’s catchment area.12

In the CSQ, the only area that was rated worse than others was the amount of time spent in consultation. Although this likely reflects the pressure on appointment times, which is both ubiquitous throughout the NHS and intensified during the pandemic,13 previous research has shown that physicians may spend less time during remote than face-to-face consultations.2

No patient characteristic was evident that would help in allocating face-to-face appointments in a manner that would maximise patient satisfaction (appendix). While it is possible that in a larger sample trends may emerge, it is unlikely that these would be sufficiently strong as to meaningfully help in the allocation of consultations in this context.

A limitation of our study is that patients under 46 years were not represented in this sample, and previous research has shown that younger patients are often more approving of remote consultations than older patients.6,8 However, younger patients are relatively rarely encountered in general cardiology clinics, and their preference could be addressed on a case-by-case basis.

A further limitation is our lack of control or comparison group. Given the pandemic situation it was not felt safe to do this, however, direct comparisons in future work would be beneficial. Additionally, we were unable to minimise the non-response bias as all surveys were completed anonymously, preventing any follow-up of those that were unreturned.

It is likely that many patients’ views will be dynamic and may have been influenced by the ‘lockdown fatigue’, which many felt at this stage of the pandemic. Views may also change (either positively or negatively) if remote consultations become more common; further work understanding how patient views change over time would be beneficial.

Conclusion

We found that despite overall high levels of patient satisfaction, a majority of patients in cardiology outpatients would have preferred a face-to-face appointment. There was, however, heterogeneity and a portion of patients expressed a strong preference for telephone consultations. No trends were evident that might predict patient preference. Patient satisfaction is clearly an important facet of healthcare delivery and optimising this will likely involve providing choice to patients on an individualised basis.

Key messages

  • Just over half the respondents were completely satisfied with remote consultations
  • A flexible and hybrid approach is the way forward

Conflicts of interest

None declared.

Funding

None.

Study approval

Local approval was obtained from the Trust’s Research and Development and Information Governance departments.

Acknowledgements

We would like to thank the cardiology consultants at Whiston Hospital for gaining consent from their patients to participate in the survey. We would also like to thank Professor Richard Baker for his permission to use his questionnaire for this survey.

References

1. Hawrysz L, Gierszewska G, Bitkowska A. The research on patient satisfaction with remote healthcare prior to and during the covid-19 pandemic. Int J Environ Res Public Health 2021;18:5338. https://doi.org/10.3390/ijerph18105338

2. McKinstry B, Hammersley V, Burton C et al. The quality, safety and content of telephone and face-to-face consultations: a comparative study. Qual Saf Health Care 2010;19:298–303. https://doi.org/10.1136/qshc.2008.027763

3. Buvik A, Bugge E, Knutsen G, Småbrekke A, Wilsgaard T. Patient reported outcomes with remote orthopaedic consultations by telemedicine: a randomised controlled trial. J Telemed Telecare 2019;25:451–9. https://doi.org/10.1177/1357633X18783921

4. Horgan TJ, Alsabbagh AY, McGoldrick DM, Bhatia SK, Messahel A. Oral and maxillofacial surgery patient satisfaction with telephone consultations during the COVID-19 pandemic. Br J Oral Maxillofac Surg 2021;59:335–40. https://doi.org/10.1016/j.bjoms.2020.08.099

5. Martos-Pérez F, Martín-Escalante MD, Olalla-Sierra J et al. The value of telephone consultations during COVID-19 pandemic. An observational study. QJM 2021;114:715–20. https://doi.org/10.1093/qjmed/hcab024

6. Adams L, Lester S, Hoon E et al. Patient satisfaction and acceptability with telehealth at specialist medical outpatient clinics during the COVID-19 pandemic in Australia. Intern Med J 2021;51:1028–37. https://doi.org/10.1111/imj.15205

7. Chesnel C, Hentzen C, Le Breton F et al. Efficiency and satisfaction with telephone consultation of follow-up patients in neuro-urology: experience of the COVID-19 pandemic. Neurourol Urodyn 2021;40:929–37. https://doi.org/10.1002/nau.24651

8. McKenna MC, Al-Hinai M, Bradley D et al. Patients’ experiences of remote neurology consultations during the COVID-19 pandemic. Eur Neurol 2021;83:622–5. https://doi.org/10.1159/000511900

9. Baker R. Development of a questionnaire to assess patients’ satisfaction with consultations in general practice. Br J Gen Pract 1990;40:487–90. Available from: https://bjgp.org/content/40/341/487.long

10. GOV.UK. Coronavirus (COVID-19) in the UK. Available at: https://coronavirus.data.gov.uk/details/download [accessed 10 June 2022].

11. Office for National Statistics. Population ageing in the United Kingdom, its constituent countries and the European Union. London: ONS, 2012. Available from: https://webarchive.nationalarchives.gov.uk/ukgwa/20160105160709/http://www.ons.gov.uk/ons/dcp171776_258607.pdf

12. Office for National Statistics. Ethnicity and national identity in England and Wales: 2011. London: ONS, 2012. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/culturalidentity/ethnicity/articles/ethnicityandnationalidentityinenglandandwales/2012-12-11

13. YouGov. YouGov results – healthcare workers quality of care and COVID. London: YouGov, 2021. Available from: https://docs.cdn.yougov.com/8mmsg1c0bc/YouGov%20-%20Healthcare%20Workers%20Quality%20of%20Care%20and%20COVID.pdf

Cardiologist elected RCP president

Br J Cardiol 2022;29:131 Leave a comment
Click any image to enlarge
Authors:

We send our congratulations to editorial board member, Dr Sarah Clarke, who has been elected the 122nd President of the Royal College of Physicians (RCP). She is the fourth woman to hold the role and has held many roles at the RCP, including, most recently, a three-year term as clinical vice-president.

Dr Sarah Clarke
Dr Sarah Clarke

Sarah is a Consultant Cardiologist and the Clinical Director of Strategic Development at the Royal Papworth Hospital NHS Foundation Trust, Cambridge. She has a particular interest in interventional cardiology and participates in Papworth’s on-call heart attack rota.

Well known nationally and internationally, Sarah is a lead on the NHS’s Getting It Right First Time (GIRFT) programme. She is also vice-chair of the British Heart Foundation, on the board of the European Society of Cardiology, and was previously the first female president of the British Cardiovascular Society. In 2018 she was awarded a grant to attend the Women Transforming Leadership Programme at the Säid Business School in Oxford and, in the same year, was awarded the International Service Award by the President of the American College of Cardiology for her outstanding contribution to enhancing cardiovascular care and education throughout the world.

New BJC editorial board members

Br J Cardiol 2022;29:131 Leave a comment
Click any image to enlarge
Authors:

We are delighted to welcome four new members to our editorial board.

Dr Claire L Colebourn joins the editorial board as our British Society for Echocardiography (BSE) representative. Claire is President of the BSE and a Consultant Medical Intensivist at Oxford University Hospitals, where she is Clinical Lead for Critical Care Echocardiography.

Dr Claire Colebourn
Dr Claire Colebourn

Dr Madalina Garbi, a Consultant Cardiologist at the Royal Papworth Hospital NHS Foundation Trust, and President-Elect of the British Heart Valve Society (BHVS), joins as our BHVS representative.

Madalina is the topic adviser on heart valve disease for the National Institute for Health and Clinical Excellence (NICE). She also has national and international recognition as an expert in echocardiography and heart valve disease, being a regular invited speaker and chair at major UK, European and American meetings and congresses. She has co-authored several recommendations, guidelines, position papers, research papers, and invited reviews and editorials in the field of echocardiography and heart valve disease.

Dr Madalina Garbi
Dr Madalina Garbi

We are also pleased to welcome Dr Rani Khatib to our editorial board. Rani is a Consultant Pharmacist in cardiology and cardiovascular research at Leeds Teaching Hospitals NHS Trust, and a Visiting Associate Professor at the University of Leeds.

Nationally, Rani is the National Clinical Champion for PCSK9 inhibitors and Lipid Management at NHS England, and Co-Chair of the Cardiovascular Group for the UK Clinical Pharmacy Association. He is also a Science Committee Member for the European Society of Cardiology Association for Cardiovascular Nursing and Allied Professions (ACNAP).

Dr Rani Khatib
Dr Rani Khatib

Finally, we welcome Dr Raj Thakkar to the editorial board as a Primary Care Cardiovascular Society (PCCS) representative. Raj is the PCCS President Elect and chronic kidney disease lead.

Raj is a General Practitioner at Bourne End and Wooburn Green Medical Centre, and holds a number of national primary care roles. He is a national primary care work-stream co-lead for the cardiac pathways improvement programme at the NHS England, the primary care cardiology lead for the Oxford Academic Health Science Networks, and a Clinical Commissioning Director (Planned Care) for Bucks/Oxford/Berks West Integrated Care System.

Dr Raj Thakkar
Dr Raj Thakkar

Evaluation of a lipid management pathway within a local cardiac rehabilitation service

Br J Cardiol 2022;29:137–40doi:10.5837/bjc.2022.034 Leave a comment
Click any image to enlarge
Authors:

Elevated cholesterol/lipid levels, especially low-density lipoprotein cholesterol (LDL-C) are known to contribute to the development of atherosclerotic cardiovascular disease (ASCVD). The attainment of lipid targets is known to be suboptimal both globally and locally. This study aimed to evaluate the effectiveness of a lipid management pathway (LMP) in supporting attainment of lipid targets following an acute coronary syndrome (ACS) in a local cohort of cardiac rehabilitation (CR) patients.

Quantitative data were retrospectively collected from 54 CR patient records. Local lipid target attainment was benchmarked against national guidelines and pre-pathway implementation audit results.

The number of admission lipid profiles increased by 24.8% to 79.6% following implementation of the LMP. There was a 31% improvement in the number of patients achieving either a 50% reduction in LDL-C or an LDL-C level of <1.4 mmol/L. In conclusion, the LMP had a significant positive impact upon the attainment of lipid goals.

Introduction

Claire Jones, Advanced Practitioner in Cardiac Rehabilitation, Wrexham Maelor Hospital
Claire Jones

Research suggests that globally, attainment of lipid targets is poor, with significant scope for improved optimisation of lipid lowering therapy (LLT) and cardiovascular (CV) risk factor management. Evidence suggests that the key initiating event in atherogenesis is retention of low-density lipoprotein cholesterol (LDL-C). To align with this, the European Society of Cardiology and European Atherosclerosis Society (ESC/EAS) proposed new LDL-C goals in 2019,1 and revised CV risk stratification guidance (particularly relevant to high-risk and very high-risk patients).

National Institute for Health and Care Excellence (NICE) guidance for lipid management in CV disease recommends a lipid target of >40% reduction in non-high-density lipoprotein (HDL).2 However, preliminary local audit data revealed levels of LDL-C often remaining above the more recent ESC/EAS recommended level of 1.4 mmol/L, despite a >40% reduction in non-HDL. The primary focus of this study was, therefore, LDL-C levels.

Research has found that reducing LDL-C by 1 mmol/L can lead to a 22–26% reduction of major adverse CV events, and suggested there is no lower limit for these benefits.3 Despite this, low rates of LDL-C goal attainment are noted.4,5 EUROASPIRE (European Action on Secondary and Primary Prevention by Intervention to Reduce Events) IV,5 a multi-national, cross-sectional study to determine whether CV ESC/EAS prevention guidelines were being followed in everyday clinical practice, found that only 19.5% of coronary patients had LDL-C levels below 1.8 mmol/L. This evidence indicates that the ESC/EAS recommendation for LDL-C of <1.4 mmol/L is not being widely met and lower goals may be even more difficult to attain.6

A lipid management pathway (LMP) was created with the purpose of facilitating the attainment of individual lipid targets. It was designed to act as a prompting tool for clinicians, and a guide to ensure patients are monitored adequately and optimised on the most appropriate LLT for CV risk reduction. This audit aimed to evaluate the effectiveness of this pathway in improving attainment of lipid targets.

Materials and method

A retrospective, post-pathway clinical audit assessed the effectiveness of the LMP in improving the attainment of lipid level targets, focused on LDL-C targets in high-risk and very high-risk patients1 in the secondary prevention of CV disease.

The audit included all patients referred to cardiac rehabilitation (CR) following ST-elevation myocardial infarction (STEMI) or non-ST-elevation myocardial infarction (NSTEMI) between 1 June 2020 and 1 December 2020. Standard data included hospital admission lipid profile, follow-up lipid profile during CR, and LDL-C level on admission and on discharge from CR. Lipid levels attained during CR were benchmarked against the ESC/EAS targets for high and very high-risk patients,1 and compared with results from a pre-pathway audit.

Sampling

An unbiased selection of patients was obtained by purposive sampling of all patients who attended CR and were discharged within the specified time frame. Fifty-four patients met the inclusion criteria.

Results

Demographics

Patients’ ages ranged between 48 and 94 years with a mean of 69.4 years, compared with a mean age of 67 years in the participating programmes in the recent National Audit of Cardiac Rehabilitation (NACR) Quality and Outcomes Report,7 so the sample was representative of the wider CR population in the UK.

In the post-pathway sample 37% were female (63% male) compared with 38% female (62% male) in the pre-pathway sample.

Initiating event

There was a higher rate of NSTEMI (59%) initiating events compared with STEMI (37%), consistent across genders.

Admission lipids

In the pre-pathway audit 54.8% of patients had a recorded lipid profile on admission to hospital in North Wales. In the post-pathway audit documented lipids increased to 79.6%.

Baseline and discharge lipid levels

Table 1 compares the baseline and discharge LDL-C and non-HDL levels between the pre- and post-pathway cohorts.

Table 1. Baseline and discharge low-density lipoprotein cholesterol (LDL-C) and non-high-density lipoprotein (HDL)

Baseline Discharge
Pre-pathway
(mmol/L)
Post-pathway
(mmol/L)
Pre-pathway
(mmol/L)
Post-pathway
(mmol/L)
Minimum LDL-C 0.9 1.0 0.7 0.2
Maximum LDL-C 5.6 7.4 4.3 5.3
Mean LDL-C 3.1 3.52 2.0 1.6
Minimum non-HDL 1.5 1.4 1.4 1.2
Maximum non-HDL 9.5 8.7 9.5 6.4
Mean non-HDL 4.1 4.5 2.7 2.3

LDL-C reduction

The pre-pathway audit revealed suboptimal lipid management, consistent with findings from studies across the UK and Europe. Figure 1 demonstrates the improvement in ESC/EAS1 target attainment in the six months following the introduction of the LMP. The total number of patients achieving both a LDL-C reduction of 50% and a level of below 1.4 mmol/L increased from 17% to 26%. The number achieving the target LDL-C increased from 36% to 50%, while 56% achieved a >50% reduction in LDL-C compared with 29% pre-pathway. Most notably, 76% of patients were achieving either or both of those targets in the post-pathway audit, compared with only 45% pre-pathway.

Jones - Figure 1. Comparison between 2019 European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) low-density lipoprotein cholesterol (LDL-C) target attainment pre- and post-pathway
Figure 1. Comparison between 2019 European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) low-density lipoprotein cholesterol (LDL-C) target1 attainment pre- and post-pathway

Results from the pre-pathway audit showed that females were less likely to achieve their lipid targets, with only 37.5% of females compared with 61.5% of males to target by the end of their CR. This again was consistent with findings from other larger studies. Interestingly, females were more likely to achieve a >50% reduction in LDL-C levels than males in the post-pathway audit cohort, while males were more likely to have an LDL-C level of <1.4 mmol/L. When looking at the combined target of a >50% reduction in LDL-C and LDL-C level of <1.4 mmol/L, males were more than twice as likely to attain the target than females with 32% and 15%, respectively.

Jones - Figure 2. Non-high-density lipoprotein (HDL) target (>40% reduction in non-HDL) attainment pre- and post-pathway
Figure 2. Non-high-density lipoprotein (HDL) target (>40% reduction in non-HDL)2 attainment pre- and post-pathway

Those patients classified as having had a STEMI were slightly more likely (55%) to achieve the LDL-C target of <1.4 mmol/L compared with NSTEMI (47%).

A significant 70% of STEMI patients had a more than 50% reduction in LDL-C compared with 47% of NSTEMI patients, while the combined target achievement difference between the groups is more modest with only a 5% difference (30% of STEMI patients and 25% of NSTEMI patients).

Non-HDL reduction

The percentage of those achieving the NICE target of a >40% reduction in non-HDL increased by 48% in the post-pathway group compared with the pre-pathway group (figure 2). Females were also more likely to achieve this target in the post-pathway group with 70% achieving a >40% reduction in non-HDL compared with 56% of males.

Discussion

The mean age of patients in this study is comparable with those in NACR’s 2019 Quality and Outcomes Report. Other key studies in this field have slightly lower mean ages, having excluded more elderly patients.8 More elderly patients may not be eligible for more aggressive lipid management owing to an increased risk of liver disease and polypharmacy,9 which may account for exclusion of more elderly patients from other clinical research. However, with patients living longer and more surviving myocardial infarction (MI),10 there will continue to be more elderly patients requiring CR input and effective lipid management. This study gives an accurate representation of the management of lipid levels among the local population.

There was a higher proportion of male patients in the younger age groups, with numbers in each gender group becoming more equally distributed around age 60 years. The mean female age at the time of their cardiac event was 72.9 years and the mean male age was 67.3 years. Based on current knowledge of demographical trends in coronary heart disease (CHD), the results will be relevant to the wider target population.

The rate of NSTEMI (59%) was higher than STEMI (37%), without disparity between genders, in keeping with national audit figures.10

ESC/EAS1 recommend a follow-up lipid profile four to six weeks after the start of treatment, whereas NICE2 recommends that a repeat lipid sample is taken about three months after the start of treatment. Allowing a longer period between samples may give a more accurate depiction of the effect of the current LLT, but this delay between samples has been observed locally to result in lack of follow-up lipid profiles and, potentially, missed opportunities for optimisation of LLT, perhaps owing to an average CR duration of three months.

It was felt that by re-checking at four to six weeks, those presenting with persistently elevated lipid levels despite their current LLT could be identified earlier, allowing increased opportunity during CR for discussion around concordance, diet, and other options for further optimisation of their LLT.

A marked improvement in the overall attainment of lipid target goals was observed (figure 1). LDL-C target attainment has been found to be generally poor, particularly among very high-risk groups, women, and those with a history of chronic kidney disease (CKD) and ischaemic stroke.11-14 Several themes emerge from analysis of the literature, including clinician perception of LDL-C targets,15 and under-utilisation of add-on therapies, such as ezetimibe.11-13,15,16 The pre-pathway audit supported the findings of the literature, and the LMP was, therefore, designed with these themes in mind.

ESC/EAS guidance1 recommends aiming to achieve both LDL-C of <1.4 mmol/L and a 50% reduction in LDL-C. As part of the data analysis for this study, these targets were measured both independently and in combination. The most significant improvement noted was those who achieved either an LDL-C <1.4 mmol/L, or >50% reduction, or both. This improvement points to a significant CHD risk reduction benefit to patients.

NICE’s 2014 guidance is to aim for a >40% reduction in non-HDL: 33% of patients achieved the non-HDL target in the pre-pathway cohort, compared with 61% in the post-pathway cohort – a significant improvement. Females (70%) were more likely to achieve this target than males (56%), which is unusual given the consensus among researchers that females are generally less likely to achieve their lipid targets.6 Females in the post-pathway cohort were also more likely to have >50% reduction in LDL-C. There was no gender demographic discrepancy between the cohorts to account for this, and the mean baseline LDL-C and non-HDL levels were also similar, hence, it can be assumed that the LMP facilitated an improvement in lipid target achievement, particularly in females.

Limitations

The sample size was small, and while smaller sample sizes have potential to lack accuracy,17 the cohort was representative demographically of the target population, as demonstrated by its consistency with national cardiac audit data.

The retrospective collection of data is a recognised limitation. The data for this study were not collected for the sole purpose of the study and, therefore, data extraction was less straightforward.

Inevitably, optimisation of lipid-lowering therapy, if not achieved with the initial LLT, takes longer, owing to the need to adequately trial different therapies. It is, therefore, acknowledged that a longer follow-up period could have rectified this and offered richer data, potentially offering a more accurate analysis of the LMP as a tool to support lipid target attainment.

Conclusion and recommendations

The findings indicate that the development and implementation of the LMP has been successful in improving the attainment of lipid goals, beyond those achieved in other parts of the UK and Europe.

The ability of CR programmes to facilitate lipid goal attainment has been highlighted. Non-medical prescribers may have further complemented this, although as full pharmacological data were not collected as part of this audit, it is not possible to draw this conclusion without further audit taking place. To date, there are no other published studies evaluating any other such tools, so this study offers valuable insight into the potential a LMP can provide in improving lipid levels in a post-ACS cohort of CR patients, thus supporting CV risk reduction.

Key messages

  • The use of a lipid management pathway (LMP) appears to have had a significant impact upon the attainment of lipid goals
  • Future investment in cardiac rehabilitation (CR) services could further enhance the attainment of lipid goals, allowing increased opportunities for patient monitoring, education and lipid-lowering treatment (LLT) optimisation
  • CR clinicians are in a prime position to support cardiovascular risk reduction, which includes the reduction of low-density lipoprotein cholesterol (LDL-C) to help prevent future disease progression and incidence of myocardial infarction (MI)

Conflicts of interest

None declared.

Funding

None.

Study approval

The main ethical risks with clinical audit identified by The Healthcare Quality Improvement Partnership18 include the maintenance of anonymity and confidentiality. The data collection proforma was designed so as not to include any patient identifiable information and the information was gathered by the sole investigator.

Editors’ note

See accompanying article by Khan and Rakhit in this issue.

References

1. Mach F, Baigent C, Catapano AL et al. ESC/EAS 2019 guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020;41:111–88. https://doi.org/10.1093/eurheartj/ehz455

2. National Institute for Health and Care Excellence. Cardiovascular disease: risk assessment and reduction, including lipid modification. CG181. London: NICE, 2014. Available from: https://www.nice.org.uk/guidance/cg181

3. Collins R, Reith C, Emberson J et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 2016;388:2532–61. https://doi.org/10.1016/S0140-6736(16)31357-5

4. Wong ND, Chuang J, Wong K, Pham A, Neff D, Marrett E. Residual dyslipidemia among United States adults treated with lipid modifying therapy (data from National Health and Nutrition Examination Survey 2009–2010). Am J Cardiol 2013;112:373–9. https://doi.org/10.1016/j.amjcard.2013.03.041

5. Kotseva K, Wood D, De Bacquer D et al.; EUROASPIRE Investigators. EUROASPIRE IV: a European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol 2016;23:636–48. https://doi.org/10.1177/2047487315569401

6. Harris DE, Lacey A, Akbari A et al. Achievement of European guideline-recommended lipid levels post-percutaneous coronary intervention: a population-level observational cohort study. Eur J Prev Cardiol 2021;28:854–61. https://doi.org/10.1177/2047487320914115

7. British Heart Foundation. The national audit of cardiac rehabilitation: quality and outcomes report 2019. London: BHF, 2019. Available from: https://www.bhf.org.uk/informationsupport/publications/statistics/national-audit-of-cardiac-rehabilitation-quality-and-outcomes-report-2019

8. Zafrir B, Saliba W, Jaffe R, Sliman H, Flugelman MY, Sharoni E. Attainment of lipid goals and long-term mortality after coronary-artery bypass surgery. Eur J Prev Cardiol 2019;26:401–08. https://doi.org/10.1177/2047487318812962

9. Zhang N, Sundquist J, Sundquist K, Ji J. An increasing trend in the prevalence of polypharmacy in Sweden: a nationwide register-based study. Front Pharmacol 2020;11:326. https://doi.org/10.3389/fphar.2020.00326

10. National Institute for Cardiovascular Outcomes Research (NICOR). Myocardial ischaemia national audit project: 2019 summary report (2017/2018 data). London: NICOR, 2019. Available from: https://www.nicor.org.uk/wp-content/uploads/2019/09/MINAP-2019-Summary-Report-final.pdf

11. Farmakis I, Zafeiropoulos S, Pagiantza A et al. Low-density lipoprotein cholesterol target value attainment based on 2019 ESC/EAS guidelines and lipid-lowering therapy titration for patients with acute coronary syndrome. Eur J Prev Cardiol 2020;27:2314–17. https://doi.org/10.1177/2047487319891780

12. Ferrieres J, De Ferrari GM, Hermans MP et al. Predictors of LDL-cholesterol target value attainment differ in acute and chronic coronary heart disease patients: results from DYSIS II Europe. Eur J Prev Cardiol 2018;25:1966–76. https://doi.org/10.1177/2047487318806359

13. Halcox JP, Tubach F, Lopez-Garcia E et al. Low rates of both lipid-lowering therapy use and achievement of low-density lipoprotein cholesterol targets in individuals at high-risk for cardiovascular disease across Europe. PLoS One 2015;10:e0115270. https://doi.org/10.1371/journal.pone.0115270

14. Harris DE, Lacey A, Akbari A et al. Early discontinuation of P2Y12 antagonists and adverse clinical events post-percutaneous coronary intervention: a hospital and primary care linked cohort. J Am Heart Assoc 2019;8:e012812. https://doi.org/10.1161/JAHA.119.012812

15. Laufs U, Karmann B, Pittrow D. Atorvastatin treatment and LDL cholesterol target attainment in patients at very high cardiovascular risk. Clin Res Cardiol 2016;105:783–90. https://doi.org/10.1007/s00392-016-0991-z

16. Banefelt J, Lindh M, Svensson MK, Eliasson B, Tai M. Statin dose titration patterns and subsequent major cardiovascular events in very high-risk patients: estimates from Swedish population-based registry data. Eur Heart J Qual Care Clin Outcomes 2020;6:323–31. https://doi.org/10.1093/ehjqcco/qcaa023

17. Polit DF, Beck CT. Essentials of nursing research: appraising evidence for nursing practice. 9th ed. China: Walters Kluwer, 2018.

18. Healthcare Quality Improvement Partnership. Guide to managing ethical issues in quality improvement or clinical audit projects. London: HQIP, 2017. Available from: https://www.hqip.org.uk/wp-content/uploads/2017/02/guide-to-managing-ethical-issues-in-quality-improvement-or-clinical-audit-projects.pdf

Secondary prevention lipid management following ACS: a missed opportunity?

Br J Cardiol 2022;29:129–31doi:10.5837/bjc.2022.035 Leave a comment
Click any image to enlarge
Authors:
First published online 9th November 2022

Acute coronary syndrome (ACS) is one of the leading causes for morbidity and mortality in the world despite advances in treatment as shown by both short- and long-term studies.1 Studies demonstrate that factors responsible for increased risk of future cardiovascular events are often ignored resulting in increased morbidity and mortality.1,2 Despite the significant reduction of in-hospital mortality in patients with ACS, the overall mortality and morbidity remains high due to missed opportunities to optimise treatment.3 The Global Registry of Acute Coronary Events (GRACE) conducted in centres in Belgium and the United Kingdom (UK) shows a long-term signal of recurrent events, such that in-hospital mortality was 3%, 4% and 5% at five-year follow up and that mortality was 15% and 18% for Belgium and UK patients, respectively.4 The GRACE study showed that patients with a higher GRACE score were at higher risk compared to low and moderate scores, and 68%, 86% and 97% deaths occurred in patients with ST-elevation myocardial infarction (STEMI), ACS and unstable angina, respectively, after initial hospital discharge. Patients with non-ST segment elevated myocardial infarction (NSTEMI) were found to have poor prognosis at six-month follow up, compared to STEMI patients, which was most likely due to patients being on less-than-optimal treatment. Medication compliance among patients is highest in the first month after ACS and Cheng et al., reported that from patients discharged on aspirin, beta blocker and statins, 34% patients had stopped at least one medicine and 12% had stopped all three medications a month after ACS.5 Only 40–45% patients were adherent with beta blocker or statins one to two years following ACS.

European Society of Cardiology (ESC) guidelines recommend low-density lipoprotein (LDL) below 1.4 mmol/L in patients post ACS, which differs from UK National Institute for Health and Care Excellence (NICE) guideline recommendations of 1.8 mmol/L and 1.4 mmol/L in very-high-risk patients only.6,7 The fifth European survey of Cardiovascular Disease prevention and Diabetes (EUROASPIRE V) survey showed that only 30% of post-ACS patients had low-density lipoprotein cholesterol (LDL-C) levels <1.8 mmol/L one year after discharge.8 The ACS EuroPath survey showed a considerable lack of physicians’ compliance with guidelines in managing lipid lowering in patients post ACS.9

UK practice

NHS patients are followed up depending on local resources within a few months to a year and, as there is no systematic approach to ensuring compliance and up-titration of secondary prevention drugs post-discharge, most patients may not receive optimal medical therapy. The heterogeneity of lipid management across various international guidelines and adherence to these guidelines varies amongst clinicians. NICE guidelines recommend high-dose atorvastatin 80 mg and to recheck lipid levels in three months’ time, with the aim to reduce LDL-C levels by at least 40%, as recommended by the Joint British Societies (JBS3).10 If statins are contraindicated or not tolerated, ezetimibe should be offered as an alternative lipid-lowering therapy and if insufficient, bempedoic acid and ezetimibe combination therapy should be initiated. If target levels are not achieved, patients should be referred to a lipid clinic for consideration of PCSK9 inhibitor therapy. Most patients who develop side effects during the first few weeks unfortunately may miss this opportunity, due to delay in initial clinic review increasing their future cardiovascular risk.

In comparison, the ESC advised different target LDL-C levels based on the patient risk and the recommended levels were <1.8 mmol/L in high-risk patients and <1.4 mmol/L in very-high-risk patients. Patients who develop an ischaemic event within two years of the previous event should have even lower target LDL-C levels <1.0 mmol/L. The latest ESC guidelines emphasise the use of combination therapies, initially with ezetimibe and then PCSK9 inhibitors. These recommendations are based mainly on the findings of FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects With Elevated Risk) and ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment with Alirocumab) trials, which showed significant risk reduction in patients who were higher risk for future cardiovascular events.11,12 The American Heart Association (AHA) and American College of Cardiologists (ACC) guidelines recommend combination therapy of statins and a non-statin therapy to achieve the target LDL-C levels <1.8 mmol/L in high-risk patients.13 These patients initially should be commenced on a maximally tolerated dose of statins and ezetimibe, and if the LDL-C levels remain >1.8 mmol/L, then they should be considered for PCSK9 inhibitor therapy.

In non-diabetic adult patients with LDL-C levels ≥1.81–4.89 mmol/L at a 10-year atherosclerotic cardiovascular disease (ASCVD) risk of 7.5% to <20%, if the decision about statin therapy is uncertain, it is recommended to consider measuring coronary artery calcification. SWEDEHEART is a nationwide registry for Swedish hospital patients that have had a MI and this showed variability from 40–75% in achieving the target LDL-C levels. The optimisation of medical therapies for secondary prevention in these patients has got worse during the COVID-19 pandemic.14

The article by Claire Jones in this issue of the BJC reports an improvement of 31% in the number of patients achieving either a 50% reduction in LDL-C or an LDL-C level of <1.4mmol/L, and patients having their admission lipid profile improved from 24.8% to 79.6% after implementation of the pathway.15 About 26% patients achieve both an LDL-C reduction of 50% and a level of below 1.4 mmol/L (increased from 17%) after attending the cardiac rehabilitation programme. Similarly, the percentage of patients achieving the target LDL-C level increased from 36% to 50%, whereas >50% reduction in LDL-C level was achieved by 56% patients in comparison to 29% pre-pathway. Remarkably, 76% of patients achieved either one or both of those targets post-pathway, compared with 45% patients pre-pathway.

Cardiac rehabilitation and lipid management

This study showed that cardiac rehabilitation programmes may significantly improve the lipid management of patients post-ACS, which could be due to increased patients’ adherence in the immediate post-ACS period and higher motivation. Most patients get seen at least a few months after the initial event, which might be too late to optimise medical therapies as the patient may lose motivation by that time and may also become less compliant with treatment. Hence, cardiac rehabilitation may the perfect opportunity to fill this gap and optimise secondary prevention lipid therapies. This study also rightly pointed out the difference in follow-up lipid profile checks between ESC/EAS and NICE guidelines. ESC/EAS recommends a follow-up lipid profile four to six weeks after the start of treatment, whereas NICE recommends a repeat lipid sample three months after start of the therapy. Patients who have persistently high LDL-C after four to six weeks of treatment are likely to benefit from more aggressive lipid management therapies to reduce their future ASCVD risk and cardiac rehabilitation is perhaps the best opportunity to address this. Cardiac rehabilitation nursing staff work according to specific pathways, and it provides them with the opportunity to monitor patient’s lipid profile and optimise medical therapy accordingly, due to their more frequent interaction early on with patients following ACS.

In summary, an early intervention cardiac rehabilitation-based lipid management pathway may be the best opportunity to address the challenges in managing dyslipidaemia in patients with ACS to reduce their future risk. This model can also be extrapolated to up-titration of other secondary prevention drugs including angiotensin-converting enzyme inhibitors, mineralocorticoid receptor antagonists and beta blockers. This has the advantage of early intervention aiding compliance, achieving secondary prevention targets and improving long-term clinical outcomes.

Conflicts of interest

None declared.

Editors’ note

See accompanying article by Jones in this issue.

References

1. Abu-Assi E, López-López A, González-Salvado V et al. The risk of cardiovascular events after an acute coronary event remains high, especially during the first year, despite revascularization. Rev Esp Cardiol (Engl Ed) 2016;69:11–8. https://doi.org/10.1016/j.rec.2015.06.015

2. Alnasser SMA, Huang W, Gore JM et al. Late consequences of acute coronary syndromes: Global Registry of Acute Coronary Events (GRACE) follow-up. Am J Med 2015;128:766–75. https://doi.org/10.1016/j.amjmed.2014.12.007

3. Alings M, Descamps O, Guillon B et al. Implementation of clinical practices and pathways optimizing ACS patients lipid management: Focus on eight European initiatives. Atheroscler Suppl 2020;42:e59–e64. https://doi.org/10.1016/j.atherosclerosissup.2021.01.010

4. Fox KA, Carruthers KF, Dunbar DR, et al. Underestimated and under-recognized: The late consequences of acute coronary syndrome (Grace UK-Belgian study). Eur Heart J 2010;31:2755–64 https://doi.org/10.1093/eurheartj/ehq326

5. Cheng K, Ingram N, Keenan J, Choudhury RP. Evidence of poor adherence to secondary prevention after acute coronary syndromes: Possible remedies through the application of New Technologies. Open Heart 2015;2:e000166. https://doi.org/10.1136/openhrt-2014-000166

6. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Eur Heart J 2019;41:111–88. https://doi.org/10.1093/eurheartj/ehz455

7. NHS Accelerated Access Collaborative. Summary of national guidance for lipid management for primary and secondary prevention of cardiovascular disease. NHS choices. Available from: https://www.england.nhs.uk/aac/publication/summary-of-national-guidance-for-lipid-management/ (last accessed 31st October 2022)

8. De Backer G, Jankowski P, Kotseva K et al. Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries. Atherosclerosis 2019;285:135–46. https://doi.org/10.1016/j.atherosclerosis.2019.03.014

9. Landmesser U, Pirillo A, Farnier M et al. Lipid-lowering therapy and low-density lipoprotein cholesterol goal achievement in patients with acute coronary syndromes: The ACS patient pathway project. Atheroscler Suppl 2020;42:e49–e58. https://doi.org/10.1016/j.atherosclerosissup.2021.01.009

10. JBS3 board. Joint British Societies’ consensus recommendations for the prevention of cardiovascular disease (JBS3). Heart 2014;100(Suppl 2):ii1–ii67. http://doi.org/10.1136/heartjnl-2014-305693

11. Sabatine MS, De Ferrari GM, Giugliano RP, et al. Clinical benefit of evolocumab by severity and extent of coronary artery disease. Circulation 2018;138:756–66. https://doi.org/10.1161/CIRCULATIONAHA.118.034309

12. Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med 2018;379:2097–107. https://doi.org/10.1056/NEJMoa1801174

13. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APHA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019;139:e1082–e1143. https://doi.org/10.1161/CIR.0000000000000625

14. Lidin M, Lyngå P, Kinch-Westerdahl A, Nymark C. Patient delay prior to care-seeking in acute myocardial infarction during the outbreak of the coronavirus SARS-CoV2 pandemic. Eur J Cardiovasc Nurs 2021;20:752–9. https://doi.org/10.1093/eurjcn/zvab087

15. Jones C. Evaluation of a lipid management pathway within a local cardiac rehabilitation service. Br J Cardiol 2022;29(4) https://doi.org/10.5837/bjc.2022.034

COVID-19 related myopericarditis and cardiac tamponade: a diagnostic conundrum

Br J Cardiol 2022;29:155–7doi:10.5837/bjc.2022.036 Leave a comment
Click any image to enlarge
Authors:

We report the case of a 45-year-old man presenting with worsening shortness of breath and chest tightness on a background of type 2 diabetes mellitus, hypertension and stable angina. He felt generally unwell and had a productive cough two weeks prior to presentation. Initial examination found quiet heart sounds and reduced air entry bi-basally on auscultation. Electrocardiography (ECG) demonstrating lateral T-wave flattening and ongoing chest tightness directed management towards an acute coronary syndrome (ACS). However, negative troponin I and positive D-dimer prompted investigation with computed tomography pulmonary angiogram (CTPA) identifying a 3.5 cm thickness pericardial effusion and no pulmonary embolism. Initial COVID-19 nasopharyngeal swabs were negative for SARS-CoV-2. Echocardiography identified features consistent with cardiac tamponade prompting pericardiocentesis. Over 1,000 ml of straw-coloured aspirate was drained with significant clinical improvement, and the patient was discharged with plans for urgent outpatient cardiac magnetic resonance imaging (MRI). Interestingly, despite multiple negative nasopharyngeal swabs for COVID-19, serum antibodies to SARS-CoV-2 were detected.

Case presentation

A 45-year-old man presented to the emergency department with a 10-day history of feeling unwell, non-exertional chest tightness, shortness of breath and reduced exercise tolerance. He found no relief with sublingual glyceryl trinitrate and complained of a productive, green cough. A COVID-19 nasopharyngeal assay prior to admission was negative for SARS-CoV-2. Past medical history included type 2 diabetes mellitus, hypertension and stable angina. There was no significant history of tobacco, alcohol or illicit substance use. On examination the patient was haemodynamically stable with positive findings of quiet heart sounds and reduced bi-basal air entry. The admission electrocardiogram (ECG) found new changes of lateral T-wave inversion (figure 1), so empirical treatment for acute coronary syndrome (ACS) was commenced. Admission biochemistry of note was raised inflammatory markers, a raised D-dimer and a normal high-sensitivity troponin I.

Meah - Figure 1. Admission electrocardiogram (ECG): T-wave inversion in the lateral leads
Figure 1. Admission electrocardiogram (ECG): T-wave inversion in the lateral leads
Meah - Figure 2. Admission chest X-ray: acute change of globular heart, suggestive of significant pericardial effusion
Figure 2. Admission chest X-ray: acute change of globular heart, suggestive of significant pericardial effusion
Meah - Figure 3. Computed tomography pulmonary angiogram (CTPA): moderate-large pericardial effusion, small bilateral pleural effusions
Figure 3. Computed tomography pulmonary angiogram (CTPA): moderate-large pericardial effusion, small bilateral pleural effusions

Further investigations included a repeat troponin (negative), chest X-ray (figure 2) and computed tomography pulmonary angiogram (CTPA), which demonstrated a 3.5 cm thickness pericardial effusion and small bilateral atelectasis/pleural effusions (figure 3). Microbiological investigations were negative for COVID-19: polymerase chain reaction (PCR), urine microscopy and cultures, and blood cultures. Differential diagnoses shifted from thromboembolic event to a constrictive/peri-myocarditis picture.

Intravenous antibiotics were commenced to cover for a respiratory infection (community-acquired pneumonia), and colchicine twice daily initiated for symptomatic pericarditis. However, the patient continued to deteriorate and became tachypnoeic and pyrexial (39.2°C). Repeat COVID-19 swab and blood cultures were negative.

Echocardiography revealed a large global effusion with right atrial systolic collapse, right ventricular diastolic collapse and mitral valve inflow variation – features consistent with cardiac tamponade (figure 4). The patient underwent urgent pericardiocentesis in the catheter lab and a large volume of straw-coloured fluid was aspirated (and sent for analysis). A drain was left in situ with a plan for removal in 24–72 hours or until dry. Repeat echocardiogram 24 hours later showed a 1.2 cm organised effusion and approximately 1,100 ml of fluid had been aspirated. At this point, the patient had been afebrile for >48 hours and felt better symptomatically.

Meah - Figure 4. Echocardiogram prior to pericardiocentesis. Measurements: 2.3–3.8 cm anteriorly, 1.5 cm posteriorly, 3.4 cm laterally, 3.9–4.3 cm apically and 2.2 cm behind the right atrium
Figure 4. Echocardiogram prior to pericardiocentesis. Measurements: 2.3–3.8 cm anteriorly, 1.5 cm posteriorly, 3.4 cm laterally, 3.9–4.3 cm apically and 2.2 cm behind the right atrium

Unfortunately, pericardial aspirate sent for biochemistry and further analysis was unable to be carried out due to COVID-19-related laboratory restrictions. However, microbiological assessment found pus cells, with no organisms seen on Gram stain or cultures.

Investigations to rule out other causes of pericarditis included; a negative vascular work-up (rheumatoid factor, connective tissue disorder screen, cyclic citrullinated peptide [CCP] antibodies, antineutrophil cytoplasmic antibodies [cANCA]), a negative hepatitis serology, a negative antistreptolysin O test, erythrocyte sedimentation rate (ESR) (raised at 86 mm/hr), and a raised immunoglobulin (Ig)A (5.36 g/L; reference range 0.40–3.50 g/L) with normal IgG/IgM. Interestingly, despite multiple negative COVID-19 swabs, the SARS-CoV-2 antibody was positive on biochemical analysis.

Discussion

In March 2020 the World Health Organisation officially declared COVID-19 a global pandemic, with the index case thought to be as early on as early December 2019.1 Caused by the pathogen severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), it rapidly disseminated across the world from its point of origin in Wuhan, China. Primarily compromising the respiratory system, COVID-19 presents with a spectrum of symptoms from entirely asymptomatic to acute respiratory distress syndrome (ARDS). Interestingly, and pertinent to this case report, COVID-19 has many extra-pulmonary presentations and complications, and we, as clinicians, need to be aware of them. The pathophysiology of COVID-19 can be grossly simplified into fusion between virus and cell membrane via binding at the angiotensin-converting enzyme 2 (ACE2) receptor, expressed in lung tissue, as well as other organs.2 The pathophysiology linking COVID-19 infection and myocarditis can be explained by the expression of ACE2 by cardiac myocytes and entry into the cell by binding the spike protein to the receptor.3 Epidemiological data on COVID-19 and cardiac injury comes with a particular limitation – the process of diagnosing myopericarditis. However, early data found around 7% incidence of myopericarditis and an increased mortality in patients with COVID-19 and associated cardiac injury.4

The application of the abovementioned principles may provide an explanation for this case report, however, despite the knowledge of extra-pulmonary manifestations of COVID-19, there is little in the literature about cardiac tamponade as a life-threatening complication.

There are several causes of cardiac tamponade, with the most common being pericarditis, malignant, iatrogenic or idiopathic.5 Infectious diseases account for the most common cause of cardiac tamponade.6 Diagnosis of cardiac tamponade is clinical (Beck’s triad is often implemented – quiet heart sounds, raised jugular venous pressure and hypotension), but ECG can also be used (ECG may show widespread low voltages) and/or radiology (a simple film of the chest may show an enlarged mediastinum and a globular cardiac silhouette). The echocardiograph can aid in diagnosis and management due to its quick, non-invasive nature. The European Society of Cardiology (ESC) have described some observational features of the heart and pericardium during cardiac tamponade.5

Early identification of cardiac tamponade is imperative, and management time critical, to prevent complete loss of cardiac output. At the point of discovery, intervention is primary, following with aetiological assessment. Pericardiocentesis is the definitive management and often patients require pre- and post-procedure monitoring in a high-dependency/intensive-care setting. Image-guided drainage of the effusion allows for safe and effective pericardiocentesis. Supportive management involves adequate oxygenation – this is of particular concern in a case such as this one. If the cause of the tamponade is SARS-CoV-2 then patients may also present with respiratory compromise requiring mechanical ventilation – in cardiac tamponade this can have antagonistic effects to the physiological compensation methods employed by the body and can lead to significant haemodynamic instability.7

Meah - Figure 5. Cardiac magnetic resonance imaging: short-axis delayed enhancement image with Gadovist demonstrating circumferential pericardial enhancement
Figure 5. Cardiac magnetic resonance imaging: short-axis delayed enhancement image with Gadovist demonstrating circumferential pericardial enhancement

Unique to our case, following pericardiocentesis our patient went on to have further radiological assessment with magnetic resonance imaging (MRI) six weeks post-admission. Assessment of the pericardium found global pericardial enhancement with circumferential mild thickening of the pericardium measuring up to 4 mm, signs of oedema and late enhancement of the pericardium with no remaining pericardial effusion. However, a septal bounce was still present. As the repeat echocardiogram and cardiac MRI (figure 5) showed resolution of pericardial effusion, the patient was booked in for routine cardiology follow-up.

Key messages

  • Acute pericarditis complicated by a pericardial effusion can be an uncommon presentation of COVID-19 and should be considered as it can be potentially life-threatening and is treatable with pericardiocentesis
  • In patients presenting with a background of cardiac pathology or demonstrating cardiac pathology, imaging such as cardiac magnetic resonance or echocardiography is highly recommended
  • Cardiac tamponade/pericarditis may present in a number of ways and it is important to recognise clinical and radiological features
  • Diagnosis of COVID-19 is still in its rudimentary stage and one should be aware of the pitfalls of COVID-19 swab tests, i.e. swabs could be false negative while the antibody test is positive, as in our case
  • Surrogate markers such as D-dimer, lymphocyte count and B-type naturietic peptide (BNP), although not diagnostic, may be clues to COVID infection, and one should have a high index of suspicion of COVID-related myocarditis/effusion in patients presenting with shortness of breath and/or chest pain

Conflicts of interest

None declared.

Funding

None.

Patient consent

Both verbal and written informed consent were obtained from the patient.

References

1. Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomed 2020;91:157–60. https://doi.org/10.23750/abm.v91i1.9397

2. Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: a review. Clin Immunol 2020;215:108427. https://doi.org/10.1016/j.clim.2020.108427

3. Siripanthong B, Nazarian S, Muser D et al. Recognizing COVID-19-related myocarditis: the possible pathophysiology and proposed guideline for diagnosis and management. Heart Rhythm 2020;17:1463–71. https://doi.org/10.1016/j.hrthm.2020.05.001

4. Buckley BJR, Harrison SL, Fazio-Eynullayeva E, Underhill P, Lane DA, Lip GYH. Prevalence and clinical outcomes of myocarditis and pericarditis in 718,365 COVID-19 patients. Eur J Clin Invest 2021;51:e13679. https://doi.org/10.1111/eci.13679

5. Jensen J, Poulsen S, Molgaard H. Cardiac tamponade: a clinical challenge. E-Journal of Cardiology Practice 2017;15. Available at: https://www.escardio.org/Journals/E-Journal-of-Cardiology-Practice/Volume-15/Cardiac-tamponade-a-clinical-challenge

6. Dudzinski DM, Mak GS, Hung JW. Pericardial diseases. Curr Probl Cardiol 2012;37:75–118. https://doi.org/10.1016/j.cpcardiol.2011.10.002

7. Cooper JP, Oliver RM, Currie P, Walker JM, Swanton RH. How do the clinical findings in patients with pericardial effusions influence the success of aspiration? Br Heart J 1995;73:351–4. https://doi.org/10.1136/hrt.73.4.351

Highlights from the BCS Annual Conference 2022: 100 years in cardiology

Br J Cardiol 2022;29:134–6 Leave a comment
Click any image to enlarge
Authors:
First published online 9th November 2022

The British Cardiovascular Society (BCS) Annual Conference 2022 was held on the 6–8th June in Manchester, UK. This year saw a return to meeting in-person, drawing delegates away from their Zoom screens and welcoming them back to the Manchester Central Convention Complex. Moreover, this year marked the centenary of the society and were honoured by a visit from Her Royal Highness, The Princess Royal. Dr Alexandra Abel reports selected highlights from BCS 2022.

100 years in cardiology

Born in 1922 and originally known as “The Cardiac Club”, the British Cardiovascular Society (BCS) is the world’s oldest professional cardiac society. To celebrate “100 years in cardiology”, five centenary lectures were given at BCS 2022 by world-renowned speakers (… three of whom were called John): Professor John Camm (heart rhythm); Professor Barbara Casadei (cardiovascular research in the UK); Professor John McMurray: (heart failure); Professor John Deanfield (coronary artery disease); and Professor Catherine Otto (cardiac imaging). The centenary lectures charted the impressive evolution of cardiovascular science over the last century, but I particularly enjoyed learning about the history of the society and its founding members.

BCS 2022

The BCS was founded by a group of physicians, which included Sir Thomas Lewis and Sir James Mackenzie. The original object of the club was: “the advancement of cardiology and the promotion of friendship among those interested in diseases of the heart.”1 It was a rather exclusive club, and members risked eviction if they missed two consecutive meetings without satisfactory explanation! A century later, the BCS has evolved into a thriving charitable organisation for “the advancement of knowledge of diseases of the heart and circulation for the benefit of the public.” Though, one would hope the promotion of friendship has remained part of the hidden curriculum of the society.

Professor Camm (St. George’s University Hospitals NHS Foundation Trust, London) explained that Sir Thomas Lewis had a great friendship (and rivalry) with Sir James Mackenzie. Together, they founded the journal Heart. Lewis hated the term “cardiologist” and wanted us to be called “cardiovascular specialists”. It is apt, therefore, that the BCS is now a “cardiovascular society”. This terminology also serves to encompass and celebrate the range of professionals involved in cardiovascular care. Professor Camm explained that Lewis’ great contribution in arrhythmology was the study of atrial fibrillation (AF). Lewis once remarked, “the notion of the patient continuing to live with an auricle incapable of contraction is a somewhat novel idea. It seems necessary to devote a little study to this condition.” One hundred years on, there has been rather more than a little study in this area; at BCS 2022, there were several sessions dedicated to AF, covering topics from screening to new approaches in AF ablation. I’d like to think Sir Thomas would have enjoyed the debate between eminent electrophysiologists on whether all whales are in AF. That’s all whales, not all of Wales. Apparently, at least one whale is in sinus rhythm.

For anyone who wishes to explore the history of the BCS in greater depth, I would highly recommend The BCS Museum (http://www.bcsmuseum.org/). The collection includes an archive of manuscripts, original papers, and biographical material. In addition, “100 voices” is a series of recorded oral histories available as podcasts on the BCS website in the members area. The centenary edition of Heart also showcases an excellent collection of commentaries and reviews, celebrating 100 years of cardiology.

Women in Cardiology

The fifteen founding members of The Cardiac Club were men. Eighteen years later, in 1940, Dr Janet Aitken and Dr Doris Baker were the first women physicians to become members of the society.2 We’ve come a long way in supporting women in cardiology over the last century, but there is still work to be done. The BCS Women in Cardiology (WIC) team (https://www.womenincardiology.uk/) aim to increase the number of women coming into training and support those already working in the specialty.

Mr Simon Flemming (Barts Health NHS Trust, London) is probably the first orthopaedic surgeon to speak at the BCS annual conference. At BCS 2022, he shared his experience in allyship and advocacy. Civility and respect produce better outcomes (including staff retention and patient outcomes); however, bullying and harassment is still present in some specialties, including cardiology, and disproportionately affects women. Mr Flemming explained that one of the reasons cultural change is so difficult within large organisations like the NHS, is that the current model has already worked for the people at the top. His advice to all was:

  1. don’t be a passive bystander – what you permit, you promote; and
  2. systems change is needed (not just personal responsibility): we need to change people’s core values and how they view the world in which they exist.

He noted that successful cultural transformation often allows people to make mistakes but expects them to learn from them and do better.

Dr Sarah Birkhoelzer (University of Oxford) discussed flexible training and WIC. Among the main reasons trainees give for their choice of subspecialty are:

  1. working acceptable hours and
  2. working conditions.

Flexible and less than full time (LTFT) training is becoming an increasingly desirable option for trainees and consultants. The number of consultants working LTFT has been rising over the last decade both for women and men. Dr Birkhoelzer emphasised the need to make this an accessible option, and to support those who choose LTFT at any stage of their career.

Trainees regularly spend more hours than they are contracted each week in service provision (not including the extra hours required for audits, research, or preparing for exams). Dr Birkhoelzer emphasised that we should not wear exhaustion as a badge of pride. Physicians are 1.5 times more likely to die by suicide than the rest of the population and female physicians have double the risk of suicide. Her take-home message was to check in with our colleagues and ask them: “How are you?”.

My main highlight of BCS 2022 was attending the WIC dinner, which was held at the Grand Pacific. Thank you to Dr Rebecca Dobson, BCS WIC representative, for organising this brilliant event. I have never seen so many women in cardiology in one room – all with different stories to tell. I left feeling a sense of community that is often lost in the modern NHS.

The WIC team host regular webinars and online chats. These can be viewed and accessed on their events page (https://www.womenincardiology.uk/events). You can also follow them on Twitter @BCSWIC (https://twitter.com/bcswic).

A royal visit

We were extremely fortunate to welcome The Princess Royal to BCS 2022. Her Royal Highness (HRH) Princess Anne attended the conference in person to deliver a short address, during which she praised the work being done by the WIC team to encourage more women to consider a career in cardiology. HRH was also able to observe an echocardiogram, performed on a volunteer. HRH pointed out the need for excellent communication during examinations and investigations. We might forget that routine procedures, such as echocardiograms, are entirely alien to many patients. HRH reminded us of the need to explain what we are doing every step of the way – an important message since many of us have likely forgotten what it is like not to know what an echo should involve.

Health inequalities in cardiovascular disease

Professor Amitava Banerjee (University College London) delivered an incredibly important “hot topic” on health inequalities. You are four times more likely to die prematurely from cardiovascular disease in the most deprived areas of the UK, compared with the least deprived areas. Internationally, the low-income countries carry most of the burden of disease. Professor Banerjee emphasised the need to move on from describing disparities to addressing inequalities in practical terms.

Professor Banerjee explained that we are aiming for justice, but for justice to prevail, we must first understand what barriers are in place, and how to remove them. There is a need for research and innovation in low-income countries; however, countries with the highest disease burden have the lowest number of publications. Professor Banerjee recommended journals waive their fees for low-income countries. Moreover, traditionally research has been quite discovery oriented, but we haven’t implemented all of what we know – Professor Banerjee emphasised the need to focus on the implementation of evidence in under-served areas, and greater coverage of global health in our curriculum.

Professor Vijay Kunadian (Newcastle University) is the first female professor of interventional cardiology in the UK. She delivered an excellent talk in relation to her role as commissioner for the Lancet Commission on reducing the global burden of cardiovascular disease in women by 2030. Professor Kunadian explained that women do not just have traditional risk factors for cardiovascular disease (e.g., factors associated with pregnancy; higher breathing rates during intervention etc.). Over a third of deaths in women worldwide are from cardiovascular disease; however, it is under-recognised, under-diagnosed (e.g., under-referred for angiography), under-treated (e.g., under prescribed medications such as beta-blockers), and women are under-represented in clinical trials.3

Professor Kunadian shared the overarching recommendations of the commission:

  1. close knowledge gaps (e.g., more women in randomised controlled trials);
  2. enhance awareness of cardiovascular disease in women;
  3. target well-established sex-specific, under-recognised risk factors (e.g., hypertension, dyslipidaemia, etc.);
  4. strengthen healthcare systems and engage health professionals.

I would highly recommend reading the full report,3 as well as related comment,4 and perspectives.5

The Young Investigator Award

The Young Research Worker’s Prize was inaugurated in 1974 to celebrate young researchers in the field of cardiovascular medicine. The prize later became known as The Young Investigator Award (YIA) and included separate basic and clinical science categories to allow a broad range of work to be considered. At BCS 2022, the top five competitors had the unenviable task of condensing months (or years) of work into a five-minute presentation, followed by five minutes of questions from the judging panel.

Dr Raghav Bhatia (St. George’s University Hospitals NHS Trust, London) discussed the prevalence and diagnostic significance of novel 12-lead ECG patterns following COVID-19 infection in elite soccer players; Dr Ziwen Li (University of Edinburgh) demonstrated a multi-omics approach to generate novel mechanistic insights and new targets for cardiovascular regeneration in the ischaemic adult heart; Dr Hamish MacLachlan (St. George’s, University of London) presented outcomes of a nationwide cardiac screening programme in young individuals; Dr Christopher Orsborne (University of Manchester) presented a novel internally validated risk predication model for adverse cardiac outcome in Fabry Disease; and Dr Marco Spartera (University of Oxford) demonstrated that reduced left atrial rotational flow is independently associated with the risk of embolic brain infarcts.

Dr Christopher Orsborne was declared the winner of the YIA 2022. Many congratulations to Dr Orsborne, and to the four runners up, on their hard work and excellent presentations.

Diary dates and resources

  • For further information about the goings on at BCS 2022, please search the hashtag #BSC100 and #BCS2022 on Twitter. In particular, see the tweets of @SarahHudsonUK, who comprehensively documents cardiology conferences for the benefit of others.
  • The BCS Annual Conference 2023 will be held on the 5–7th June 2023.

Conflicts of interest

None declared

Dr Alexandra Abel
Clinical teaching fellow
Hull York Medical School, Castle Hill Hospital, HU16 5JQ
([email protected])

References

1. Coats CJ. History of the British Cardiovascular Society. Heart 2022;108:761–6. http://doi.org/10.1136/heartjnl-2021-320139

2. Boon NA. British Cardiovascular Society: from club to community. Heart 2022;108:749–50. http://doi.org/10.1136/heartjnl-2021-320140

3. Vogel B, Acevedo M, Appelman Y, et al. The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030. Lancet 2021;397:2385–438. https://doi.org/10.1016/S0140-6736(21)00684-X

4. Mocumbi AO. Women’s cardiovascular health: shifting towards equity and justice. Lancet 2021;397:2315–7. https://doi.org/10.1016/S0140-6736(21)01017-5

5. Lane R. Roxana Mehran: driving force in women’s cardiovascular health. Lance 2021;397(10292):2326. https://doi.org/10.1016/S0140-6736(21)01100-4

Hot topics in atherosclerosis and cardiovascular disease

Br J Cardiol 2022;29:132–4 Leave a comment
Click any image to enlarge
Authors:

HEART UK’s recent 35th Annual Medical Scientific Meeting blended a face-to-face meeting with virtual attendance to showcase the latest developments within the lipid community. Held at the University of Warwick on 6th–8th July 2022, Dr Andreas Tridimas reports its highlights.

The role of pharmacy

HEART UK - The Cholesterol Charity

Dr Rani Khatib (Leeds Teaching Hospitals NHS Trust) outlined the scale of non-adherence in the secondary prevention of coronary artery disease (CAD) using a cohort of 503 patients with CAD. Non-adherence to at least one secondary prevention medication occurred in 43.5% of patients. Statins topped the list of non-adherance medications, contributing to 66.7% of overall non-adherence.1

Dr Rani Khatib - HEART UK 2022
Dr Rani Khatib

To improve adherence, a novel joint cardiology pharmacist and cardiologist medicines optimisation clinic was established for patients discharged following myocardial infarction (MI). Here barriers to adherence were identified and discussed. Rates of non-adherence fell by 42.6%–70.8% three to six months post-clinic. Moreover, readmission rates also declined, suggesting this model may have a wider role in improving adherence.2 The pharmacy-led cardiology innovative medicines clinic provides better access to newer lipid-lowering therapies, helps in achieving low-density lipoprotein cholesterol (LDL-C) targets, and in tackling statin intolerance.

CVD risk and gender reassignment

Professor Devi Nair - HEART UK 2022
Professor Devi Nair

Despite between 200–500,000 people in the UK identifying as transgender,3 Professor Devi Nair (Royal Free Hospital, London) highlighted that there is still not clear, high-quality evidence on how cross-hormone treatment influences long-term cardiovascular (CV) risk. Gender-affirming hormone therapy improves gender dysphoria and wellbeing in transgender patients, but the CV effects of such treatments are poorly defined due to the limited number of longitudinal studies focused on CV outcomes. To date, most studies have been observational, with heterogeneity of hormone regimens.4 Robust clinical evidence is needed to help manage CV risk in this population to avoid any potential health inequality.

Fats versus carbs

Professor Bruce Griffin - HEART UK 2022
Professor Bruce Griffin

Professor Bruce Griffin (University of Surrey) reiterated the well-established notion that all forms of LDL-C are atherogenic and that, beyond doubt, higher LDL-C correlates with coronary heart disease risk.5,6 Thus caution, particularly when considering the paucity of long-term CV outcome data, is needed in relation to the lipid-modifying effects of certain diets, such as ketogenic low-carbohydrate, high-fat diets, whereby LDL-C may be seen to rise significantly.7

Statin myopathy and myositis

Professor Hector Chinoy - HEART UK 2022
Professor Hector Chinoy

Severe myopathy with statin use remains very rare, Professor Hector Chinoy (Salford Royal NHS Trust) reminded delegates, telling them that keeping perspective is key given the proven ability of statins to prevent atherosclerotic complications.8 To assist clinical teams in determining whether muscle symptoms are likely to be statin related, he pointed the audience towards the Statin-Associated Muscle Symptom Clinical Index (SAMS-CI),9 which is a useful online tool for this purpose. In those found to have significant creatine kinase elevation with prior or current statin use, he discussed the rare presentation of statin-associated necrotising myopathy, an autoimmune condition, which can be assessed for with anti-HMGCR antibody testing. Positive anti-HMGCR antibody levels are strongly associated with this immune-mediated necrotising myopathy.10

CCTA in the lipid clinic

Dr Jonathan Rodrigues - HEART UK 2022
Dr Jonathan Rodrigues

Dr Jonathan Rodrigues (Royal United Hospitals Bath NHS Foundation Trust) highlighted recent advances in CAD CV risk prediction. Traditional approaches such as coronary calcium scoring rely on the identification of coronary calcification, which represents the end stage of atherosclerotic disease. CAD, however, is an inflammatory process that can be detected far earlier by mapping the perivascular fat attenuation index, using coronary CT angiography (CCTA). Combining this information with traditional CV risk factors, technologies such as CaRi-Heart®, are poised to significantly improve our identification and risk stratification of CAD.11

Devolution differences

A session bringing together presenters from the four nations of the UK (Kate Shipman, Chichester; Paul Hamilton, Belfast; Sara Jenks, Edinburgh; and Yee Ping Teoh, Wrexham) outlined the regional variation in lipid management across the UK, highlighting some clear differences, most notably within familial hypercholesterolaemia (FH) identification. Northern Ireland is currently leading the way, with 23% of FH cases having been identified, followed by Wales at 14.5%, considerably above the UK average of under 8% identification. A key factor in achieving this success appears to be having dedicated FH nurses to work on cascade screening.

Lipoprotein(a): CV risk and emerging therapies

Professor Sam Tsimikas (University of California San Diego, USA) gave the latest updates on lipoprotein(a). He outlined how statins can significantly increase plasma lipoprotein(a) levels by approximately 8–24%, depending on the dose and statin used.12 Pelacarsen, an RNA-interfering injectable medication, has been shown in early studies to lower lipoprotein(a) levels by approximately 80%. Outcome data is not expected until 2025. Unlike previous therapeutics working via reducing ApoB production, hepatic steatosis does not appear to be an issue. At least four further drugs to lower lipoprotein(a) are in earlier stage trials and it is hoped all this research will lead to an effective treatment for reducing this risk factor for atherosclerotic vascular disease.

UK view

Dr Jai Cegla - HEART UK 2022
Dr Jai Cegla

There is much regional variation in lipoprotein(a) testing, Dr Jai Cegla (Imperial College Healthcare Trust, London) told the meeting highlighting that, in their recent survey, 20% of lipid clinics reported they still did not offer its measurement. She directed the audience to the 2019 HEART UK consensus statement on lipoprotein(a), whose key statements included the recommendation to screen first-degree relatives of those with a raised serum lipoprotein(a) >200 nmol/L, due to the high CV risk conferred at such levels.13

Severe FH – from a lethal to a manageable disorder

The prestigious Myant lecture was given this year by Professor Frederick Raal (University of Witwatersrand, Johannesburg, South Africa), a titan within the FH community. He took the audience on a journey to show just how much progress has been made in the management of homozygous FH (HoFH). Professor Raal’s unit has one of the largest cohorts, if not the largest cohort, of HoFH patients in the world. From a previously lethal disorder in childhood, many of these patients are now adults with well-controlled cholesterol, through an array of lipid-lowering therapies, which are either LDL-receptor (LDLR) dependent or independent, depending on the residual LDLR function.

Professor Frederick Raal (right) is presented with his Myant lecturer award by Professor Handrean Soran, Chair, HEART UK Medical Scientific and Research Committee
Professor Frederick Raal (right) is presented with his Myant lecturer award by Professor Handrean Soran, Chair, HEART UK Medical Scientific and Research Committee

Professor Raal outlined how the arteries of a 20-year-old HoFH patient are exposed to same amount of cholesterol as a healthy 80-year-old individual. This highlights how it is crucial to start treatment early and continue this for life. Professor Raal finished his lecture with a promising look to the future. Could gene therapy eventually lead to a potential ‘cure’ for some with HoFH, by inducing LDLR expression in the liver, he asked?

Dr Andreas Tridimas
Consultant in Chemical Pathology and Metabolic Medicine
Countess of Chester Hospital, Chester

References

1. Khatib R, Marshall K, Silcock J et al. Adherence to coronary artery disease secondary prevention medicines: exploring modifiable barriers. Open Heart 2019;6:e000997. http://doi.org/10.1136/openhrt-2018-000997

2. Khatib R, Khan M, Barrowcliff A, et al. Innovative, centralised, multidisciplinary medicines optimisation clinic for PCSK9 inhibitors. Open Heart 2022;9:e001931. http://doi.org/10.1136/openhrt-2021-001931

3. Government Equalities Office. Factsheet: Trans people in the UK. Crown copyright 2018. ISBN: 978-1-78655-673-8 https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/721642/GEO-LGBT-factsheet.pdf (last accessed 3 October 2022)

4. Aranda G, Halperin I, Gomez-Gil E et al. Cardiovascular risk associated with gender affirming hormone therapy in transgender population. Front. Endocrinol 2021;12:718200 https://doi.org/10.3389/fendo.2021.718200

5. Borén J, Chapman MJ, Krauss RM et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 2020;41:2313–30. https://doi.org/10.1093/eurheartj/ehz962

6. Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 2017;38:2459–72 https://doi.org/10.1093/eurheartj/ehx144

7. Burén, J, Ericsson M, Damasceno NRT et al. A ketogenic low-carbohydrate high-fat diet increases LDL cholesterol in healthy, young, normal-weight women: a randomized controlled feeding trial. Nutrients 2021;13:814. https://doi.org/10.3390/nu13030814

8. Harper CR, Jacobson TA. The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis. Curr Opin Lipidol 2007;18:401–8. https://doi.org/10.1097/MOL.0b013e32825a6773

9. Rosenson RS, Miller K, Bayliss M et al. The Statin-Associated Muscle Symptom Clinical Index (SAMS-CI): revision for clinical use, content validation, and inter-rater reliability. Cardiovasc Drugs Ther 2017;31:179–86. https://doi.org/10.1007/s10557-017-6723-4

10. Christopher-Stine L, Casciola-Rosen LA, Hong G et al. A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum 2010;62:2757–66. https://doi.org/10.1002/art.27572

11. Oikonomou EK, Antonopoulos AS, Schottlander D et al. Standardized measurement of coronary inflammation using cardiovascular computed tomography: integration in clinical care as a prognostic medical device. Cardiovasc Res 2021;117:2677–90. https://doi.org/10.1093/cvr/cvab286

12. Tsimikas S, Gordts PLSM, Nora C et al. Statin therapy increases lipoprotein(a) levels. Eur Heart J 2020;41:2275–84. https://doi.org/10.1093/eurheartj/ehz310

13. Cegla J, Neely RDG, France M et al. HEART UK Medical, Scientific and Research Committee. HEART UK consensus statement on lipoprotein(a): A call to action. Atherosclerosis 2019;291:62–70. https://doi.org/10.1016/j.atherosclerosis.2019.10.011